This is a non-core endpoint: only basic statistics are computed.
Malignant neoplasm of other and ill-defined digestive organs
C3_DIGESTIVE_ORGANS_NAS
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519870 |
1. Apply sex-specific ruleNone |
519870 |
2. Check conditionsNone |
519870 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
324 |
4. Check minimum number of eventsNone |
324 |
5. Include endpointsNone |
324 |
6. Filter based on genotype QC (FinnGen only) |
305 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF9
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm of other and ill-defined digestive organs
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm of other and ill-defined digestive organs, including Hilmo
- Malignant neoplasm of digestive organs
- Malignant neoplasm of digestive organs, including Hilmo
- Solid cancers
- Malignant neoplasm
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 305 | 138 | 167 |
| Unadjusted period prevalence (%) | 0.06 | 0.05 | 0.08 |
| Median age at first event (years) | 75.07 | 75.61 | 74.62 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 324
- Matched controls
- 3237
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
Z51.5
ICD-10 Finland
Palliative care
25.6
166.3
136
89
130
Kela drug reimbursment
Malignant tumour
+∞
156.2
137
*
C26.9
ICD-10 Finland
Malignant neoplasm: Ill-defined sites within the digestive system
+∞
146.2
129
*
H02AB02
ATC
dexamethasone; systemic
67.1
144.5
81
16
8140/3-C26.9
ICD-O-3
Adenocarcinoma, NOS, of gastrointestinal tract, NOS
+∞
119.3
107
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
81.8
75
*
A03FA01
ATC
metoclopramide; systemic, rectal
8.7
77.8
133
240
JJ2AT
NOMESCO Finland
Biopsy of liver with ultrasound guidance
52.0
77.0
45
10
JN4BD
NOMESCO Finland
Extensive body CT
13.9
74.9
77
71
JN4AD
NOMESCO Finland
Body CT examination
11.9
74.6
87
97
C26.0
ICD-10 Finland
Malignant neoplasm: Intestinal tract, part unspecified
+∞
65.9
61
*
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
+∞
64.8
60
*
N02AA05
ATC
oxycodone; systemic
6.7
62.4
146
354
A04AA02
ATC
granisetron; systemic, transdermal
714.3
61.9
59
*
8000/3-C26.9
ICD-O-3
Neoplasm, malignant of gastrointestinal tract, NOS
+∞
61.4
57
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
59.2
55
*
A04AA01
ATC
ondansetron; systemic, rectal
18.0
56.5
48
31
R18
ICD-10 Finland
Ascites
25.2
55.2
40
18
C78.6
ICD-10 Finland
Secondary malignant neoplasm of retroperitoneum and peritoneum
+∞
50.3
47
*
L01BC06
ATC
capecitabine; oral
+∞
50.3
47
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
39.4
37
*
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
11.5
36.7
40
39
WX302
NOMESCO Finland
Thoracal epidural anesthesy
12.1
30.7
32
29
C26.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of digestive system
+∞
28.5
27
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
28.5
27
*
JAH00
NOMESCO Finland
Laparotomy
11.7
28.1
30
28
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
27.5
26
*
D37.7
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Other digestive organs
30.9
27.3
36
13
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
293.9
27.1
27
*
XX3DW
NOMESCO Finland
Time consuming IT work
7.5
27.0
41
61
WZC00
NOMESCO Finland
Treatment plan or consultation
3.6
26.9
126
481
C80.92
ICD-10 Finland
Malignant tumor without specified localization adenocarcinoma
+∞
26.4
25
*
JN3AD
NOMESCO Finland
Abdominal CT examination
4.5
23.7
68
182
D37.6
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Liver, gallbladder and bile ducts
35.2
22.8
29
9
WZC30
NOMESCO Finland
Teaching
4.1
21.7
70
204
116
Kela drug reimbursment
Prostate cancer
+∞
21.1
20
*
C80.0
ICD-10 Finland
Malignant neoplasm, primary site unknown, so stated
+∞
20.0
19
*
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
+∞
20.0
19
*
8936/3-C26.9
ICD-O-3
Gastrointestinal stromal tumor of gastrointestinal tract, NOS
+∞
20.0
19
*
8010/3-C26.9
ICD-O-3
Carcinoma, NOS, of gastrointestinal tract, NOS
+∞
18.9
18
*
C22.9
ICD-10 Finland
Malignant neoplasm: Liver, unspecified
+∞
18.9
18
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
74.4
18.9
21
*
JAH01
NOMESCO Finland
Laparoscopy
8.0
18.5
26
35
JA3AT
NOMESCO Finland
Cathetrisation of abdominal cavity with ultrasound guidance
24.5
18.0
25
11
A04AA55
ATC
palonosetron, combinations; systemic
+∞
17.9
17
*
8000/3-C26.0
ICD-O-3
Neoplasm, malignant of intestinal tract, NOS
+∞
17.9
17
*
8140/3-C26.0
ICD-O-3
Adenocarcinoma, NOS, of intestinal tract, NOS
+∞
17.9
17
*
B01AB10
ATC
tinzaparin; parenteral
4.3
17.7
50
131
K56.6
ICD-10 Finland
Other and unspecified intestinal obstruction
7.6
17.2
25
35
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
+∞
16.8
16
*
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
16.8
16
*
WF002
NOMESCO Finland
Radical radiotherapy
83.9
14.7
16
*
C49.49
ICD-10 Finland
Malignant tumor of connective tissue and soft tissue of the abdomen other or unspecified tumor
+∞
14.7
14
*
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
+∞
14.7
14
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
14.7
14
*
L02AE02
ATC
leuprorelin; implant, parenteral
78.5
13.7
15
*
D37.9
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Digestive organ, unspecified
78.5
13.7
15
*
JF1AB
NOMESCO Finland
Passage examination of small bowell with X-ray
35.7
13.6
17
5
166
Kela drug reimbursment
Dalteparin and tinzaparin (treatment for more than 6 months)
+∞
13.6
13
*
8090/3-C44.3
ICD-O-3
Basal cell carcinoma, NOS, of skin of other and unspecified parts of face
+∞
13.6
13
*
L03AA13
ATC
pegfilgrastim; parenteral
145.7
13.5
14
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.3
13.3
56
192
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.5
13.1
121
628
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
+∞
12.6
12
*
C76.2
ICD-10 Finland
Malignant neoplasm of other and ill-defined sites: Abdomen
+∞
12.6
12
*
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
12.6
12
*
189
Kela drug reimbursment
Imatinib
+∞
12.6
12
*
UJF32
NOMESCO Finland
Coloscopy
2.5
12.5
101
492
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
10.7
12.2
23
23
TPH04
NOMESCO Finland
Cathetrisation of vein
2.5
11.6
90
428
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
+∞
11.5
11
*
C25.9
ICD-10 Finland
Malignant neoplasm: Pancreas, unspecified
+∞
11.5
11
*
A79
ICPC
Malignancy NOS
+∞
11.5
11
*
L03AA02
ATC
filgrastim; parenteral
124.1
11.5
12
*
ZX120
NOMESCO Finland
Intravenous
3.9
11.4
35
97
JN3BD
NOMESCO Finland
Extensive abdominal CT
3.3
11.0
45
151
JFB00
NOMESCO Finland
Partial resection of small intestine
29.1
10.8
14
5
WD415
NOMESCO Finland
Demanding antibody therapy of methastized malignancy
+∞
10.5
10
*
Z08.0
ICD-10 Finland
Follow-up examination after surgery for malignant neoplasm
+∞
10.5
10
*
L01XE01
ATC
[U] imatinib
+∞
10.5
10
*
Y77
ICPC
Malignant neoplasm prostate
+∞
10.5
10
*
D77
ICPC
Malignant digestive neopl other/NOS
+∞
10.5
10
*
C16.9
ICD-10 Finland
Malignant neoplasm: Stomach, unspecified
+∞
10.5
10
*
JEA00
NOMESCO Finland
Appendectomy
5.2
10.4
22
45
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.2
10.3
118
662
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
4.2
10.1
28
72
J90
ICD-10 Finland
Pleural effusion, not elsewhere classified
4.9
9.9
22
47
XW4AT
NOMESCO Finland
Biopsy of other inner organ with ultrasound guidance
56.7
9.7
11
*
115
Kela drug reimbursment
Breast cancer
+∞
9.4
9
*
8480/3-C26.9
ICD-O-3
Mucinous adenocarcinoma of gastrointestinal tract, NOS
+∞
9.4
9
*
JAL01
NOMESCO Finland
Laparoscopic biopsy of peritoneum
+∞
9.4
9
*
C56.00
ICD-10 Finland
Malignant tumor of the ovary without histology
+∞
9.4
9
*
C80.90
ICD-10 Finland
Malignant tumor without specified localization without histology
+∞
9.4
9
*
WD505
NOMESCO Finland
Simple enzyme inhibitor or similar therapy of methastized malignancy
+∞
9.4
9
*
PJA12
NOMESCO Finland
Sentinel node biopsy
+∞
9.4
9
*
QX3AT
NOMESCO Finland
Ultrasound guided biopsy of subcutaneous tissue
37.8
9.1
11
*
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
37.8
9.1
11
*
B01AB05
ATC
enoxaparin; parenteral
2.1
9.0
109
619
HAB40
NOMESCO Finland
Wedge excision of mammary gland
51.4
8.7
10
*
JN4CD
NOMESCO Finland
Very extensive body CT
10.4
8.6
16
16
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
3.3
8.5
34
112
A49.9
ICD-10 Finland
Bacterial infection, unspecified
2.6
8.5
57
250
H01CB03
ATC
lanreotide; parenteral
92.3
8.4
9
*
176
Kela drug reimbursment
Regorafenib
+∞
8.4
8
*
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
+∞
8.4
8
*
C22.1
ICD-10 Finland
Malignant neoplasm: Intrahepatic bile duct carcinoma
+∞
8.4
8
*
C78.2
ICD-10 Finland
Secondary malignant neoplasm of pleura
+∞
8.4
8
*
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
4.1
8.3
23
59
TPX10
NOMESCO Finland
Implantation of vascular injection port
8.5
8.2
17
21
K83.1
ICD-10 Finland
Obstruction of bile duct
12.1
8.1
14
12
JA2AT
NOMESCO Finland
Abdominal puncture with ultrasound guidance
34.2
8.1
10
*
R19.0
ICD-10 Finland
Intra-abdominal and pelvic swelling, mass and lump
10.4
8.1
15
15
SPAT1255
SPAT
Intravenous administration of medicine
3.2
8.0
33
111
I26.9
ICD-10 Finland
Pulmonary embolism without mention of acute cor pulmonale
3.1
7.8
34
118
ZX090
NOMESCO Finland
Other technic of radiotherapy
46.1
7.7
9
*
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
3.0
7.7
35
125
JN1CG
NOMESCO Finland
Extensive MRI examination of upper part of abdomen with high intensity magnet
9.2
7.6
15
17
A06AH03
ATC
naloxegol; oral
25.7
7.6
10
*
J94.8
ICD-10 Finland
Other specified pleural conditions
7.9
7.5
16
21
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
81.8
7.4
8
*
C25.0
ICD-10 Finland
Malignant neoplasm: Head of pancreas
+∞
7.3
7
*
C80.99
ICD-10 Finland
Malignant tumor without specified localization or histology
+∞
7.3
7
*
A04AD12
ATC
aprepitant; systemic
+∞
7.3
7
*
C78.8
ICD-10 Finland
Secondary malignant neoplasm of other and unspecified digestive organs
+∞
7.3
7
*
YN7BD
NOMESCO Finland
Extensive CT examination of spine for dose design of radiotherapy
+∞
7.3
7
*
C44.51
ICD-10 Finland
Basocellular carcinoma of the skin on the torso
+∞
7.3
7
*
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
+∞
7.3
7
*
C79.30
ICD-10 Finland
Secondary malignant tumor of the cerebrum
+∞
7.3
7
*
ZX080
NOMESCO Finland
Image guided radiotherapy
+∞
7.3
7
*
Z51.0
ICD-10 Finland
Radiotherapy session
+∞
7.3
7
*
PJ2AT
NOMESCO Finland
Biopsy of lymphnode with ultrasound guidance
+∞
7.3
7
*
WPA44, ,
SPAT
+∞
7.3
7
*
WPA10
NOMESCO Finland
Proactive palliative care treatment plan
30.7
7.2
9
*
L02BG04
ATC
letrozole; oral
40.9
6.8
8
*
NK6AN
NOMESCO Finland
Total body bone isotope imaging
40.9
6.8
8
*
WW200, ,
SPAT
0.4
6.6
28
670
SPAT1083
SPAT
Initiation and monitoring of IV fluid therapy
3.6
6.5
22
65
H01CB02
ATC
octreotide; parenteral
71.1
6.4
7
*
JFF10
NOMESCO Finland
Loop enterostomy
71.1
6.4
7
*
GA4YT
NOMESCO Finland
Puncture of pleura with ultrasound guidance
4.2
6.4
17
42
WW500
NOMESCO Finland
Blood transfusion
5.7
6.4
17
31
OAB44, ,
SPAT
0.1
6.3
*
183
C49.4
ICD-10 Finland
Malignant neoplasm: Connective and soft tissue of abdomen
+∞
6.3
6
*
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
+∞
6.3
6
*
HA003
NOMESCO Finland
Radiotherapy after partial ablation of mammary gland
+∞
6.3
6
*
L01EA01
ATC
imatinib; oral
+∞
6.3
6
*
C20.91
ICD-10 Finland
Malignant tumor of the rectum invasive carcinoma
+∞
6.3
6
*
WD225
NOMESCO Finland
Demanding therapy of methastized malignancy with hormones
+∞
6.3
6
*
C80.98
ICD-10 Finland
Malignant tumor without specified localization other specified histology
+∞
6.3
6
*
128
Kela drug reimbursment
Cancers of female genital organs
+∞
6.3
6
*
8240/3-C26.9
ICD-O-3
Neuroendocrine tumor, NOS, of gastrointestinal tract, NOS
+∞
6.3
6
*
C76.8
ICD-10 Finland
Malignant neoplasm of other and ill-defined sites: Overlapping lesion of other and ill-defined sites
+∞
6.3
6
*
C22.0
ICD-10 Finland
Malignant neoplasm: Liver cell carcinoma
+∞
6.3
6
*
C17.9
ICD-10 Finland
Malignant neoplasm: Small intestine, unspecified
+∞
6.3
6
*
Z03.1
ICD-10 Finland
Observation for suspected malignant neoplasm
10.3
6.1
11
11
TimeCodeWAS
↥TODO / Current known limitations:
- Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
- Legend / how to read the glyphs.
- Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
- Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
- Download CSV.
- No filters and sorters.
- Limited amount of endpoints (~400) having TimeCodeWAS data.
- Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Carcinoembryonic Ag [Mass/volume] in Serum or Plasma
2039-6 [3003785]
2039-6 [3003785]
1.7e+00
3.0e+00
5.4e+00
1.0e+50
—
5.1e+00
—
cases:7.43%
controls:1.43%
cases:14.55%
controls:0.81%
cases:25.39%
controls:0.15%
cases:2.48%
controls:0.00%
—
—
cases:47.83%
controls:0.57%
—
—
24
46
299
3182
47
26
276
3202
82
5
241
3223
8
0
315
3228
—
44
18
48
3132
—
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
6768-6 [3035995]
1.8e-01
1.3e+00
3.6e+00
3.6e+00
4.0e+00
2.6e+00
—
cases:35.60%
controls:31.57%
cases:40.25%
controls:15.30%
cases:47.99%
controls:2.48%
cases:6.19%
controls:0.19%
cases:51.38%
controls:1.86%
cases:71.74%
controls:15.94%
—
—
115
1019
208
2209
130
494
193
2734
155
80
168
3148
20
6
303
3222
112
60
106
3162
66
502
26
2648
—
Upper gastrointestinal surgery
106 [44777669]
106 [44777669]
6.6e-01
1.8e+00
4.3e+00
1.0e+50
4.6e+00
3.0e+00
—
cases:18.27%
controls:10.38%
cases:20.12%
controls:3.87%
cases:30.96%
controls:0.62%
cases:12.07%
controls:0.00%
cases:33.94%
controls:0.53%
cases:43.48%
controls:3.62%
—
—
59
335
264
2893
65
125
258
3103
100
20
223
3208
39
0
284
3228
74
17
144
3205
40
114
52
3036
—
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
14631-6 [3006140]
3.4e-01
1.7e+00
4.2e+00
—
4.7e+00
3.3e+00
—
cases:21.36%
controls:16.26%
cases:30.03%
controls:7.22%
cases:40.25%
controls:0.96%
—
—
cases:47.25%
controls:0.81%
cases:69.57%
controls:7.71%
—
—
69
525
254
2703
97
233
226
2995
130
31
193
3197
—
103
26
115
3196
64
243
28
2907
—
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
1988-5 [3020460]
1.9e-01
9.6e-01
3.1e+00
4.1e+00
3.4e+00
1.9e+00
—
cases:52.32%
controls:47.68%
cases:50.15%
controls:27.85%
cases:55.73%
controls:5.14%
cases:19.81%
controls:0.40%
cases:60.09%
controls:4.66%
cases:72.83%
controls:28.44%
—
—
169
1539
154
1689
162
899
161
2329
180
166
143
3062
64
13
259
3215
131
150
87
3072
67
896
25
2254
—
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
2601-3 [3012095]
7.1e-01
1.6e+00
3.8e+00
—
4.2e+00
2.9e+00
—
cases:6.50%
controls:3.31%
cases:7.12%
controls:1.49%
cases:6.81%
controls:0.15%
—
—
cases:9.63%
controls:0.16%
cases:22.83%
controls:1.62%
—
—
21
107
302
3121
23
48
300
3180
22
5
301
3223
—
21
5
197
3217
21
51
71
3099
—
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
A03FA01 [21600484]
1.3e+00
2.1e+00
3.4e+00
—
—
5.5e+00
—
cases:5.88%
controls:1.73%
cases:6.50%
controls:0.87%
cases:4.64%
controls:0.15%
—
—
—
—
cases:56.52%
controls:0.51%
—
—
19
56
304
3172
21
28
302
3200
15
5
308
3223
—
—
52
16
40
3134
—
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
5894-1 [3033658]
3.0e-01
1.6e+00
4.4e+00
—
3.9e+00
2.3e+00
—
cases:10.53%
controls:7.99%
cases:13.62%
controls:3.00%
cases:22.91%
controls:0.37%
—
—
cases:16.06%
controls:0.37%
cases:25.00%
controls:3.37%
—
—
34
258
289
2970
44
97
279
3131
74
12
249
3216
—
35
12
183
3210
23
106
69
3044
—
oxycodone; oral, parenteral
N02AA05 [21604260]
N02AA05 [21604260]
7.4e-01
1.7e+00
2.8e+00
—
4.2e+00
3.5e+00
—
cases:4.64%
controls:2.26%
cases:8.05%
controls:1.61%
cases:7.74%
controls:0.50%
—
—
cases:23.85%
controls:0.47%
cases:40.22%
controls:2.06%
—
—
15
73
308
3155
26
52
297
3176
25
16
298
3212
—
52
15
166
3207
37
65
55
3085
—
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
1798-8 [3016771]
2.5e-02
1.6e+00
4.0e+00
—
4.1e+00
2.0e+00
—
cases:10.84%
controls:10.59%
cases:16.10%
controls:3.66%
cases:21.67%
controls:0.50%
—
—
cases:11.47%
controls:0.22%
cases:21.74%
controls:3.78%
—
—
35
342
288
2886
52
118
271
3110
70
16
253
3212
—
25
7
193
3215
20
119
72
3031
—
INR in Blood by Coagulation assay
34714-6 [3032080]
34714-6 [3032080]
1.2e-01
1.1e+00
2.6e+00
3.9e+00
2.1e+00
1.8e+00
—
cases:22.91%
controls:20.91%
cases:27.86%
controls:11.43%
cases:36.84%
controls:4.03%
cases:9.91%
controls:0.22%
cases:23.39%
controls:3.76%
cases:41.30%
controls:10.32%
—
—
74
675
249
2553
90
369
233
2859
119
130
204
3098
32
7
291
3221
51
121
167
3101
38
325
54
2825
—
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
1751-7 [3024561]
1.8e-01
1.1e+00
3.5e+00
—
4.2e+00
2.7e+00
—
cases:17.96%
controls:15.49%
cases:21.98%
controls:8.27%
cases:21.98%
controls:0.87%
—
—
cases:35.32%
controls:0.81%
cases:55.43%
controls:7.97%
—
—
58
500
265
2728
71
267
252
2961
71
28
252
3200
—
77
26
141
3196
51
251
41
2899
—
Cathetrisation of vein
TPH04 [2001309597]
TPH04 [2001309597]
2.3e-01
1.4e+00
3.3e+00
—
3.3e+00
3.3e+00
—
cases:5.26%
controls:4.24%
cases:4.95%
controls:1.33%
cases:4.02%
controls:0.15%
—
—
cases:4.13%
controls:0.16%
cases:20.65%
controls:0.92%
—
—
17
137
306
3091
16
43
307
3185
13
5
310
3223
—
9
5
209
3217
19
29
73
3121
—
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2951-2 [3019550]
-1.4e-02
4.3e-01
2.6e+00
4.1e+00
2.9e+00
1.2e+00
—
cases:56.97%
controls:57.31%
cases:55.11%
controls:44.39%
cases:56.66%
controls:8.55%
cases:21.67%
controls:0.46%
cases:60.09%
controls:7.76%
cases:73.91%
controls:45.46%
—
—
184
1850
139
1378
178
1433
145
1795
183
276
140
2952
70
15
253
3213
131
250
87
2972
68
1432
24
1718
—
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
14682-9 [3020564]
6.5e-02
4.5e-01
2.6e+00
3.9e+00
2.9e+00
1.3e+00
—
cases:61.61%
controls:60.07%
cases:59.44%
controls:48.33%
cases:60.37%
controls:9.91%
cases:21.36%
controls:0.53%
cases:64.68%
controls:9.03%
cases:78.26%
controls:49.59%
—
—
199
1939
124
1289
192
1560
131
1668
195
320
128
2908
69
17
254
3211
141
291
77
2931
72
1562
20
1588
—
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
20570-8 [3009542]
1.0e-01
3.9e-01
2.7e+00
4.4e+00
2.8e+00
1.2e+00
—
cases:63.78%
controls:61.43%
cases:60.06%
controls:50.43%
cases:64.40%
controls:10.66%
cases:26.93%
controls:0.43%
cases:64.68%
controls:9.78%
cases:77.17%
controls:50.76%
—
—
206
1983
117
1245
194
1628
129
1600
208
344
115
2884
87
14
236
3214
141
315
77
2907
71
1599
21
1551
—
MCH [Entitic mass]
28539-5 [3035941]
28539-5 [3035941]
1.0e-01
3.9e-01
2.7e+00
4.4e+00
2.8e+00
1.2e+00
—
cases:63.78%
controls:61.37%
cases:60.06%
controls:50.43%
cases:64.40%
controls:10.66%
cases:26.63%
controls:0.43%
cases:64.68%
controls:9.71%
cases:77.17%
controls:50.67%
—
—
206
1981
117
1247
194
1628
129
1600
208
344
115
2884
86
14
237
3214
141
313
77
2909
71
1596
21
1554
—
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
718-7 [3000963]
9.9e-02
3.9e-01
2.7e+00
4.4e+00
2.8e+00
1.2e+00
—
cases:63.78%
controls:61.46%
cases:60.06%
controls:50.50%
cases:64.40%
controls:10.81%
cases:26.93%
controls:0.43%
cases:64.68%
controls:9.75%
cases:77.17%
controls:50.76%
—
—
206
1984
117
1244
194
1630
129
1598
208
349
115
2879
87
14
236
3214
141
314
77
2908
71
1599
21
1551
—
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
30428-7 [3024731]
1.0e-01
3.9e-01
2.7e+00
4.4e+00
2.8e+00
1.2e+00
—
cases:63.78%
controls:61.40%
cases:60.06%
controls:50.46%
cases:64.40%
controls:10.72%
cases:26.63%
controls:0.43%
cases:64.68%
controls:9.75%
cases:77.17%
controls:50.76%
—
—
206
1982
117
1246
194
1629
129
1599
208
346
115
2882
86
14
237
3214
141
314
77
2908
71
1599
21
1551
—
Platelets [#/volume] in Blood
26515-7 [3007461]
26515-7 [3007461]
1.0e-01
3.9e-01
2.7e+00
4.4e+00
2.8e+00
1.2e+00
—
cases:63.78%
controls:61.40%
cases:60.06%
controls:50.50%
cases:64.40%
controls:10.72%
cases:26.63%
controls:0.43%
cases:64.68%
controls:9.75%
cases:77.17%
controls:50.79%
—
—
206
1982
117
1246
194
1630
129
1598
208
346
115
2882
86
14
237
3214
141
314
77
2908
71
1600
21
1550
—
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2823-3 [3023103]
-1.5e-02
4.2e-01
2.6e+00
4.0e+00
2.9e+00
1.2e+00
—
cases:57.28%
controls:57.65%
cases:55.42%
controls:44.95%
cases:56.66%
controls:8.67%
cases:21.36%
controls:0.50%
cases:60.55%
controls:7.79%
cases:73.91%
controls:45.81%
—
—
185
1861
138
1367
179
1451
144
1777
183
280
140
2948
69
16
254
3212
132
251
86
2971
68
1443
24
1707
—
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
26453-1 [3026361]
1.0e-01
3.9e-01
2.7e+00
4.4e+00
2.8e+00
1.2e+00
—
cases:63.78%
controls:61.40%
cases:60.06%
controls:50.50%
cases:64.40%
controls:10.72%
cases:26.63%
controls:0.43%
cases:64.68%
controls:9.78%
cases:77.17%
controls:50.79%
—
—
206
1982
117
1246
194
1630
129
1598
208
346
115
2882
86
14
237
3214
141
315
77
2907
71
1600
21
1550
—
Leukocytes [#/volume] in Blood
26464-8 [3010813]
26464-8 [3010813]
9.8e-02
3.9e-01
2.7e+00
4.4e+00
2.8e+00
1.2e+00
—
cases:63.78%
controls:61.49%
cases:60.06%
controls:50.50%
cases:64.40%
controls:10.66%
cases:26.32%
controls:0.43%
cases:64.68%
controls:9.75%
cases:77.17%
controls:50.76%
—
—
206
1985
117
1243
194
1630
129
1598
208
344
115
2884
85
14
238
3214
141
314
77
2908
71
1599
21
1551
—
Bacteria identified in Blood by Culture
600-7 [3023368]
600-7 [3023368]
2.6e-01
1.2e+00
3.7e+00
—
4.1e+00
2.1e+00
—
cases:11.76%
controls:9.32%
cases:12.38%
controls:4.03%
cases:12.69%
controls:0.37%
—
—
cases:14.22%
controls:0.28%
cases:26.09%
controls:4.13%
—
—
38
301
285
2927
40
130
283
3098
41
12
282
3216
—
31
9
187
3213
24
130
68
3020
—
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
751-8 [3013650]
3.8e-01
1.1e+00
3.0e+00
—
3.8e+00
2.9e+00
—
cases:23.84%
controls:17.63%
cases:26.01%
controls:10.10%
cases:27.24%
controls:1.80%
—
—
cases:41.74%
controls:1.58%
cases:66.30%
controls:9.78%
—
—
77
569
246
2659
84
326
239
2902
88
58
235
3170
—
91
51
127
3171
61
308
31
2842
—
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
34531-4 [3044640]
4.0e-01
8.5e-01
3.6e+00
—
4.1e+00
2.2e+00
—
cases:13.31%
controls:9.36%
cases:7.74%
controls:3.47%
cases:14.55%
controls:0.46%
—
—
cases:10.55%
controls:0.19%
cases:25.00%
controls:3.40%
—
—
43
302
280
2926
25
112
298
3116
47
15
276
3213
—
23
6
195
3216
23
107
69
3043
—
fentanyl; nasal, sublingual, transdermal
N02AB03 [21604272]
N02AB03 [21604272]
—
1.9e+00
2.5e+00
—
3.3e+00
3.1e+00
—
—
—
cases:2.17%
controls:0.34%
cases:1.86%
controls:0.15%
—
—
cases:5.05%
controls:0.19%
cases:9.78%
controls:0.48%
—
—
—
7
11
316
3217
6
5
317
3223
—
11
6
207
3216
9
15
83
3135
—
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
1742-6 [3006923]
5.4e-02
4.9e-01
2.7e+00
3.2e+00
3.0e+00
1.4e+00
—
cases:56.97%
controls:55.64%
cases:52.01%
controls:39.90%
cases:51.39%
controls:6.35%
cases:7.43%
controls:0.34%
cases:52.75%
controls:5.28%
cases:73.91%
controls:40.44%
—
—
184
1796
139
1432
168
1288
155
1940
166
205
157
3023
24
11
299
3217
115
170
103
3052
68
1274
24
1876
—
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
2000-8 [3015377]
-9.2e-02
8.1e-01
3.1e+00
—
4.0e+00
2.5e+00
—
cases:10.22%
controls:11.09%
cases:8.98%
controls:4.21%
cases:7.12%
controls:0.34%
—
—
cases:19.27%
controls:0.43%
cases:35.87%
controls:4.29%
—
—
33
358
290
2870
29
136
294
3092
23
11
300
3217
—
42
14
176
3208
33
135
59
3015
—
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
62238-1 [40764999]
2.8e-02
3.9e-01
2.5e+00
3.7e+00
2.7e+00
1.4e+00
—
cases:42.11%
controls:41.42%
cases:43.96%
controls:34.63%
cases:46.75%
controls:7.00%
cases:15.48%
controls:0.43%
cases:51.38%
controls:6.39%
cases:70.65%
controls:36.95%
—
—
136
1337
187
1891
142
1118
181
2110
151
226
172
3002
50
14
273
3214
112
206
106
3016
65
1164
27
1986
—
CBC panel - Blood by Automated count
58410-2 [40761511]
58410-2 [40761511]
-2.1e-02
3.3e-01
2.5e+00
4.4e+00
2.4e+00
1.0e+00
—
cases:51.70%
controls:52.23%
cases:42.11%
controls:34.42%
cases:44.89%
controls:6.44%
cases:15.48%
controls:0.22%
cases:38.99%
controls:5.59%
cases:57.61%
controls:32.76%
—
—
167
1686
156
1542
136
1111
187
2117
145
208
178
3020
50
7
273
3221
85
180
133
3042
53
1032
39
2118
—
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
890-4 [3001079]
2.5e-01
7.9e-01
3.8e+00
—
3.8e+00
1.9e+00
—
cases:16.41%
controls:13.29%
cases:10.53%
controls:5.08%
cases:21.67%
controls:0.62%
—
—
cases:13.76%
controls:0.37%
cases:26.09%
controls:4.79%
—
—
53
429
270
2799
34
164
289
3064
70
20
253
3208
—
30
12
188
3210
24
151
68
2999
—
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
30385-9 [3002385]
5.7e-02
3.5e-01
2.4e+00
4.2e+00
2.6e+00
1.0e+00
—
cases:39.01%
controls:37.67%
cases:39.01%
controls:31.04%
cases:44.89%
controls:6.66%
cases:17.34%
controls:0.31%
cases:45.41%
controls:5.93%
cases:56.52%
controls:31.52%
—
—
126
1216
197
2012
126
1002
197
2226
145
215
178
3013
56
10
267
3218
99
191
119
3031
52
993
40
2157
—
Calcium [Moles/volume] corrected for albumin in Serum or Plasma
29265-6 [3020059]
29265-6 [3020059]
-4.6e-01
8.3e-01
3.3e+00
—
4.2e+00
2.6e+00
—
cases:4.33%
controls:6.72%
cases:6.50%
controls:2.94%
cases:4.95%
controls:0.19%
—
—
cases:14.68%
controls:0.25%
cases:29.35%
controls:2.86%
—
—
14
217
309
3011
21
95
302
3133
16
6
307
3222
—
32
8
186
3214
27
90
65
3060
—
Treatment plan or consultation
WZC00 [2001310885]
WZC00 [2001310885]
6.7e-01
1.7e+00
—
—
4.2e+00
4.1e+00
—
cases:8.98%
controls:4.80%
cases:6.81%
controls:1.33%
—
—
—
—
cases:12.84%
controls:0.22%
cases:43.48%
controls:1.27%
—
—
29
155
294
3073
22
43
301
3185
—
—
28
7
190
3215
40
40
52
3110
—
Laboratory Visit
OMOP4822461 [32036]
OMOP4822461 [32036]
9.4e-02
3.0e-01
2.2e+00
4.2e+00
2.3e+00
9.1e-01
—
cases:67.18%
controls:65.09%
cases:65.94%
controls:58.92%
cases:67.80%
controls:19.30%
cases:44.89%
controls:1.21%
cases:67.89%
controls:17.47%
cases:79.35%
controls:60.63%
—
—
217
2101
106
1127
213
1902
110
1326
219
623
104
2605
145
39
178
3189
148
563
70
2659
73
1910
19
1240
—
Other and unspecified abdominal pain
R10.4 [45568113]
R10.4 [45568113]
-1.9e-01
2.0e+00
4.0e+00
—
3.3e+00
1.4e+00
—
cases:5.26%
controls:6.29%
cases:9.60%
controls:1.39%
cases:10.53%
controls:0.22%
—
—
cases:6.42%
controls:0.25%
cases:6.52%
controls:1.68%
—
—
17
203
306
3025
31
45
292
3183
34
7
289
3221
—
14
8
204
3214
6
53
86
3097
—
Emergency Room and Inpatient Visit
ERIP [262]
ERIP [262]
3.8e-01
1.1e+00
3.5e+00
—
3.3e+00
1.4e+00
—
cases:12.07%
controls:8.61%
cases:13.93%
controls:5.11%
cases:23.53%
controls:0.90%
—
—
cases:12.39%
controls:0.53%
cases:22.83%
controls:6.83%
—
—
39
278
284
2950
45
165
278
3063
76
29
247
3199
—
27
17
191
3205
21
215
71
2935
—
Inpatient Visit
IP [9201]
IP [9201]
1.1e-01
8.4e-01
3.1e+00
1.0e+50
3.3e+00
2.0e+00
—
cases:9.29%
controls:8.43%
cases:10.53%
controls:4.83%
cases:10.53%
controls:0.53%
cases:9.60%
controls:0.00%
cases:12.84%
controls:0.53%
cases:28.26%
controls:4.95%
—
—
30
272
293
2956
34
156
289
3072
34
17
289
3211
31
0
292
3228
28
17
190
3205
26
156
66
2994
—
Short blood count panel - Blood
55429-5 [40758558]
55429-5 [40758558]
5.9e-01
1.1e+00
2.9e+00
—
3.3e+00
1.9e+00
—
cases:11.76%
controls:6.91%
cases:8.98%
controls:3.04%
cases:9.29%
controls:0.56%
—
—
cases:12.39%
controls:0.53%
cases:21.74%
controls:4.06%
—
—
38
223
285
3005
29
98
294
3130
30
18
293
3210
—
27
17
191
3205
20
128
72
3022
—
Body CT examination
JN4AD [2001310897]
JN4AD [2001310897]
1.8e+00
3.1e+00
—
1.0e+50
1.0e+50
4.3e+00
—
cases:2.17%
controls:0.37%
cases:4.02%
controls:0.19%
—
—
cases:1.86%
controls:0.00%
cases:4.59%
controls:0.00%
cases:25.00%
controls:0.44%
—
—
7
12
316
3216
13
6
310
3222
—
6
0
317
3228
10
0
208
3222
23
14
69
3136
—
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
1920-8 [3013721]
-1.2e-01
1.1e+00
3.1e+00
—
2.9e+00
2.0e+00
—
cases:9.29%
controls:10.35%
cases:10.84%
controls:3.97%
cases:10.22%
controls:0.50%
—
—
cases:7.80%
controls:0.47%
cases:21.74%
controls:3.59%
—
—
30
334
293
2894
35
128
288
3100
33
16
290
3212
—
17
15
201
3207
20
113
72
3037
—
Supplier / Service Provider
OMOP5117446 [33004]
OMOP5117446 [33004]
-3.2e-01
1.2e-01
1.7e+00
—
3.9e+00
3.4e+00
—
cases:19.81%
controls:25.31%
cases:8.67%
controls:7.78%
cases:4.95%
controls:0.93%
—
—
cases:7.34%
controls:0.16%
cases:18.48%
controls:0.73%
—
—
64
817
259
2411
28
251
295
2977
16
30
307
3198
—
16
5
202
3217
17
23
75
3127
—
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
28540-3 [3003338]
-2.2e-02
3.3e-01
2.3e+00
4.2e+00
2.5e+00
4.3e-01
—
cases:44.58%
controls:45.14%
cases:41.49%
controls:33.80%
cases:42.72%
controls:6.82%
cases:18.89%
controls:0.34%
cases:44.95%
controls:6.18%
cases:43.48%
controls:33.30%
—
—
144
1457
179
1771
134
1091
189
2137
138
220
185
3008
61
11
262
3217
98
199
120
3023
40
1049
52
2101
—
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
19072-8 [3016431]
2.9e-01
8.6e-01
2.9e+00
—
3.3e+00
2.0e+00
—
cases:22.91%
controls:18.22%
cases:21.05%
controls:10.13%
cases:18.27%
controls:1.27%
—
—
cases:22.02%
controls:1.02%
cases:43.48%
controls:9.43%
—
—
74
588
249
2640
68
327
255
2901
59
41
264
3187
—
48
33
170
3189
40
297
52
2853
—
Emergency Room Visit
ER [9203]
ER [9203]
1.5e-01
7.9e-01
3.4e+00
1.0e+50
3.2e+00
1.5e+00
—
cases:44.89%
controls:41.11%
cases:25.39%
controls:13.32%
cases:32.51%
controls:1.52%
cases:2.17%
controls:0.00%
cases:24.77%
controls:1.30%
cases:35.87%
controls:11.33%
—
—
145
1327
178
1901
82
430
241
2798
105
49
218
3179
7
0
316
3228
54
42
164
3180
33
357
59
2793
—
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
1995-0 [3021347]
2.7e-01
8.2e-01
2.9e+00
—
3.3e+00
1.9e+00
—
cases:20.12%
controls:16.14%
cases:18.27%
controls:8.98%
cases:16.72%
controls:1.15%
—
—
cases:18.81%
controls:0.81%
cases:35.87%
controls:7.78%
—
—
65
521
258
2707
59
290
264
2938
54
37
269
3191
—
41
26
177
3196
33
245
59
2905
—
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
30383-4 [3000850]
2.6e-01
9.8e-01
2.8e+00
—
3.3e+00
1.8e+00
—
cases:9.29%
controls:7.34%
cases:6.50%
controls:2.54%
cases:5.57%
controls:0.37%
—
—
cases:5.05%
controls:0.19%
cases:14.13%
controls:2.67%
—
—
30
237
293
2991
21
82
302
3146
18
12
305
3216
—
11
6
207
3216
13
84
79
3066
—
Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma
1805-1 [3016417]
1805-1 [3016417]
-6.3e-04
2.2e+00
4.0e+00
—
—
2.6e+00
—
cases:2.48%
controls:2.48%
cases:5.57%
controls:0.65%
cases:7.74%
controls:0.15%
—
—
—
—
cases:11.96%
controls:0.98%
—
—
8
80
315
3148
18
21
305
3207
25
5
298
3223
—
—
11
31
81
3119
—
Inpatient Hospital
21 [8717]
21 [8717]
3.8e-01
9.2e-01
3.1e+00
—
3.2e+00
1.5e+00
—
cases:46.13%
controls:37.02%
cases:25.08%
controls:11.80%
cases:26.93%
controls:1.61%
—
—
cases:25.69%
controls:1.40%
cases:32.61%
controls:9.37%
—
—
149
1195
174
2033
81
381
242
2847
87
52
236
3176
—
56
45
162
3177
30
295
62
2855
—
pH of Serum or Plasma
2753-2 [3018418]
2753-2 [3018418]
2.2e-01
9.6e-01
2.9e+00
—
2.9e+00
2.0e+00
—
cases:12.38%
controls:10.19%
cases:13.62%
controls:5.67%
cases:12.07%
controls:0.74%
—
—
cases:11.01%
controls:0.68%
cases:30.43%
controls:5.59%
—
—
40
329
283
2899
44
183
279
3045
39
24
284
3204
—
24
22
194
3200
28
176
64
2974
—
Thorax X-ray examination
GD1AA [2001303617]
GD1AA [2001303617]
3.5e-01
9.3e-01
3.0e+00
—
2.7e+00
2.1e+00
—
cases:17.34%
controls:12.92%
cases:11.76%
controls:4.99%
cases:9.91%
controls:0.56%
—
—
cases:7.34%
controls:0.53%
cases:29.35%
controls:4.67%
—
—
56
417
267
2811
38
161
285
3067
32
18
291
3210
—
16
17
202
3205
27
147
65
3003
—
Bacteria [Presence] in Urine
87829-8 [36304419]
87829-8 [36304419]
3.5e-01
1.1e+00
2.7e+00
—
3.0e+00
1.7e+00
—
cases:11.76%
controls:8.58%
cases:10.53%
controls:3.84%
cases:9.29%
controls:0.65%
—
—
cases:7.80%
controls:0.40%
cases:19.57%
controls:4.10%
—
—
38
277
285
2951
34
124
289
3104
30
21
293
3207
—
17
13
201
3209
18
129
74
3021
—
Tissue Pathology biopsy report
66121-5 [40768804]
66121-5 [40768804]
5.2e-01
1.2e+00
2.3e+00
—
3.1e+00
2.0e+00
—
cases:14.24%
controls:8.95%
cases:8.36%
controls:2.76%
cases:3.72%
controls:0.40%
—
—
cases:6.42%
controls:0.31%
cases:14.13%
controls:2.25%
—
—
46
289
277
2939
27
89
296
3139
12
13
311
3215
—
14
10
204
3212
13
71
79
3079
—
Outpatient Hospital
22 [8756]
22 [8756]
3.6e-01
9.2e-01
2.7e+00
—
3.0e+00
1.7e+00
—
cases:35.91%
controls:28.10%
cases:15.79%
controls:6.97%
cases:13.31%
controls:0.99%
—
—
cases:13.30%
controls:0.74%
cases:22.83%
controls:5.11%
—
—
116
907
207
2321
51
225
272
3003
43
32
280
3196
—
29
24
189
3198
21
161
71
2989
—
Outpatient Visit
OP [9202]
OP [9202]
-1.1e-01
2.7e-01
1.1e+00
3.8e+00
1.7e+00
1.8e+00
—
cases:82.04%
controls:83.64%
cases:69.04%
controls:62.92%
cases:28.79%
controls:11.83%
cases:14.86%
controls:0.40%
cases:43.58%
controls:12.76%
cases:91.30%
controls:64.44%
—
—
265
2700
58
528
223
2031
100
1197
93
382
230
2846
48
13
275
3215
95
411
123
2811
84
2030
8
1120
—
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
51483-6 [3030467]
2.5e-01
9.8e-01
2.7e+00
—
2.9e+00
1.7e+00
—
cases:11.15%
controls:8.89%
cases:10.53%
controls:4.24%
cases:9.60%
controls:0.71%
—
—
cases:7.34%
controls:0.43%
cases:20.65%
controls:4.44%
—
—
36
287
287
2941
34
137
289
3091
31
23
292
3205
—
16
14
202
3208
19
140
73
3010
—
General Practice
1 [38004446]
1 [38004446]
1.5e-01
7.3e-01
3.0e+00
—
3.1e+00
1.4e+00
—
cases:26.01%
controls:23.17%
cases:18.27%
controls:9.70%
cases:21.36%
controls:1.30%
—
—
cases:23.85%
controls:1.37%
cases:31.52%
controls:10.44%
—
—
84
748
239
2480
59
313
264
2915
69
42
254
3186
—
52
44
166
3178
29
329
63
2821
—
Emergency Medicine
93 [38004510]
93 [38004510]
2.3e-01
9.0e-01
3.1e+00
—
2.6e+00
1.6e+00
—
cases:26.63%
controls:22.46%
cases:26.01%
controls:12.55%
cases:26.32%
controls:1.61%
—
—
cases:19.27%
controls:1.68%
cases:43.48%
controls:13.59%
—
—
86
725
237
2503
84
405
239
2823
85
52
238
3176
—
42
54
176
3168
40
428
52
2722
—
Differential panel, method unspecified - Blood
69738-3 [42870588]
69738-3 [42870588]
1.7e-01
9.9e-01
2.7e+00
—
2.5e+00
2.0e+00
—
cases:12.38%
controls:10.66%
cases:13.93%
controls:5.67%
cases:13.00%
controls:0.99%
—
—
cases:9.63%
controls:0.84%
cases:28.26%
controls:5.30%
—
—
40
344
283
2884
45
183
278
3045
42
32
281
3196
—
21
27
197
3195
26
167
66
2983
—
Gastroenterology
10 [38004455]
10 [38004455]
4.7e-01
1.1e+00
2.3e+00
1.0e+50
2.9e+00
1.8e+00
—
cases:10.84%
controls:7.03%
cases:7.43%
controls:2.66%
cases:4.33%
controls:0.43%
cases:1.55%
controls:0.00%
cases:5.96%
controls:0.34%
cases:10.87%
controls:2.00%
—
—
35
227
288
3001
24
86
299
3142
14
14
309
3214
5
0
318
3228
13
11
205
3211
10
63
82
3087
—
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
30391-7 [3002582]
2.2e-01
9.7e-01
2.7e+00
—
2.9e+00
1.6e+00
—
cases:12.69%
controls:10.47%
cases:12.07%
controls:4.93%
cases:11.15%
controls:0.84%
—
—
cases:8.72%
controls:0.53%
cases:20.65%
controls:5.21%
—
—
41
338
282
2890
39
159
284
3069
36
27
287
3201
—
19
17
199
3205
19
164
73
2986
—
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
2324-2 [3026910]
-3.2e-02
7.6e-01
3.3e+00
1.0e+50
2.7e+00
1.3e+00
—
cases:21.67%
controls:22.21%
cases:17.03%
controls:8.74%
cases:19.81%
controls:0.90%
cases:2.79%
controls:0.00%
cases:11.47%
controls:0.90%
cases:26.09%
controls:8.48%
—
—
70
717
253
2511
55
282
268
2946
64
29
259
3199
9
0
314
3228
25
29
193
3193
24
267
68
2883
—
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
50554-5 [3029287]
8.6e-02
8.2e-01
2.8e+00
—
3.0e+00
1.5e+00
—
cases:13.62%
controls:12.64%
cases:11.76%
controls:5.55%
cases:11.46%
controls:0.81%
—
—
cases:10.55%
controls:0.59%
cases:20.65%
controls:5.62%
—
—
44
408
279
2820
38
179
285
3049
37
26
286
3202
—
23
19
195
3203
19
177
73
2973
—
tinzaparin; parenteral
B01AB10 [21600981]
B01AB10 [21600981]
4.5e-01
1.9e+00
3.0e+00
—
—
3.1e+00
—
cases:1.55%
controls:0.99%
cases:3.41%
controls:0.53%
cases:3.10%
controls:0.15%
—
—
—
—
cases:9.78%
controls:0.48%
—
—
5
32
318
3196
11
17
312
3211
10
5
313
3223
—
—
9
15
83
3135
—
Oncology Clinic/Center
261QX0200X [38004268]
261QX0200X [38004268]
4.0e+00
4.0e+00
—
1.0e+50
—
—
—
cases:10.22%
controls:0.22%
cases:9.29%
controls:0.19%
—
—
cases:82.66%
controls:0.00%
—
—
—
—
—
—
33
7
290
3221
30
6
293
3222
—
267
0
56
3228
—
—
—
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
14749-6 [3013826]
2.6e-03
8.0e-01
3.0e+00
—
2.5e+00
1.7e+00
—
cases:23.53%
controls:23.48%
cases:21.98%
controls:11.25%
cases:22.91%
controls:1.52%
—
—
cases:14.68%
controls:1.46%
cases:40.22%
controls:10.48%
—
—
76
758
247
2470
71
363
252
2865
74
49
249
3179
—
32
47
186
3175
37
330
55
2820
—
Physiotherapy
R4110 [2001310233]
R4110 [2001310233]
2.1e-01
9.8e-01
3.3e+00
—
2.9e+00
1.8e+00
—
cases:7.74%
controls:6.35%
cases:4.64%
controls:1.80%
cases:4.64%
controls:0.19%
—
—
cases:3.67%
controls:0.22%
cases:9.78%
controls:1.81%
—
—
25
205
298
3023
15
58
308
3170
15
6
308
3222
—
8
7
210
3215
9
57
83
3093
—
Monocytes/Leukocytes in Blood
26485-3 [3019069]
26485-3 [3019069]
1.1e-01
9.8e-01
2.7e+00
—
2.5e+00
1.7e+00
—
cases:17.03%
controls:15.55%
cases:19.50%
controls:8.36%
cases:17.65%
controls:1.39%
—
—
cases:12.84%
controls:1.21%
cases:32.61%
controls:8.13%
—
—
55
502
268
2726
63
270
260
2958
57
45
266
3183
—
28
39
190
3183
30
256
62
2894
—
Basophils/Leukocytes in Blood
30180-4 [3022096]
30180-4 [3022096]
1.3e-01
9.7e-01
2.7e+00
—
2.5e+00
1.7e+00
—
cases:17.34%
controls:15.52%
cases:19.50%
controls:8.40%
cases:17.65%
controls:1.39%
—
—
cases:12.84%
controls:1.21%
cases:32.61%
controls:8.16%
—
—
56
501
267
2727
63
271
260
2957
57
45
266
3183
—
28
39
190
3183
30
257
62
2893
—
Basophils [#/volume] in Blood
26444-0 [3006315]
26444-0 [3006315]
1.1e-01
9.8e-01
2.7e+00
—
2.6e+00
1.6e+00
—
cases:17.96%
controls:16.45%
cases:20.43%
controls:8.80%
cases:18.58%
controls:1.49%
—
—
cases:13.76%
controls:1.21%
cases:31.52%
controls:8.70%
—
—
58
531
265
2697
66
284
257
2944
60
48
263
3180
—
30
39
188
3183
29
274
63
2876
—
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
26474-7 [3019198]
7.8e-02
9.5e-01
2.7e+00
—
2.6e+00
1.5e+00
—
cases:18.27%
controls:17.13%
cases:20.74%
controls:9.23%
cases:18.89%
controls:1.49%
—
—
cases:13.76%
controls:1.18%
cases:31.52%
controls:8.98%
—
—
59
553
264
2675
67
298
256
2930
61
48
262
3180
—
30
38
188
3184
29
283
63
2867
—
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
26478-8 [3002030]
7.8e-02
9.6e-01
2.7e+00
—
2.5e+00
1.7e+00
—
cases:17.03%
controls:15.95%
cases:19.81%
controls:8.61%
cases:17.65%
controls:1.43%
—
—
cases:12.84%
controls:1.21%
cases:32.61%
controls:8.38%
—
—
55
515
268
2713
64
278
259
2950
57
46
266
3182
—
28
39
190
3183
30
264
62
2886
—
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
26450-7 [3006504]
1.3e-01
9.7e-01
2.7e+00
—
2.5e+00
1.6e+00
—
cases:17.34%
controls:15.49%
cases:19.50%
controls:8.40%
cases:17.65%
controls:1.43%
—
—
cases:12.84%
controls:1.21%
cases:31.52%
controls:8.16%
—
—
56
500
267
2728
63
271
260
2957
57
46
266
3182
—
28
39
190
3183
29
257
63
2893
—
Eosinophils [#/volume] in Blood
26449-9 [3013115]
26449-9 [3013115]
1.4e-01
9.5e-01
2.7e+00
—
2.6e+00
1.5e+00
—
cases:19.20%
controls:17.13%
cases:20.74%
controls:9.17%
cases:18.58%
controls:1.52%
—
—
cases:14.22%
controls:1.27%
cases:31.52%
controls:8.95%
—
—
62
553
261
2675
67
296
256
2932
60
49
263
3179
—
31
41
187
3181
29
282
63
2868
—
Monocytes [#/volume] in Blood
26484-6 [3001604]
26484-6 [3001604]
1.1e-01
9.6e-01
2.7e+00
—
2.5e+00
1.5e+00
—
cases:17.96%
controls:16.33%
cases:20.12%
controls:8.80%
cases:18.58%
controls:1.49%
—
—
cases:13.30%
controls:1.21%
cases:30.43%
controls:8.70%
—
—
58
527
265
2701
65
284
258
2944
60
48
263
3180
—
29
39
189
3183
28
274
64
2876
—
Leukocytes [#/volume] in Urine
30405-5 [3018095]
30405-5 [3018095]
2.2e-01
9.1e-01
2.6e+00
—
2.9e+00
1.4e+00
—
cases:14.24%
controls:11.74%
cases:12.69%
controls:5.55%
cases:11.76%
controls:1.02%
—
—
cases:10.09%
controls:0.62%
cases:20.65%
controls:6.25%
—
—
46
379
277
2849
41
179
282
3049
38
33
285
3195
—
22
20
196
3202
19
197
73
2953
—
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
26511-6 [3018010]
3.6e-02
9.7e-01
2.7e+00
—
2.4e+00
1.6e+00
—
cases:16.10%
controls:15.61%
cases:20.12%
controls:8.71%
cases:16.72%
controls:1.39%
—
—
cases:11.93%
controls:1.18%
cases:30.43%
controls:8.32%
—
—
52
504
271
2724
65
281
258
2947
54
45
269
3183
—
26
38
192
3184
28
262
64
2888
—
Cancer Ag 19-9 [Units/volume] in Serum or Plasma
24108-3 [3022914]
24108-3 [3022914]
1.5e+00
2.9e+00
—
1.0e+50
1.0e+50
4.7e+00
—
cases:2.48%
controls:0.59%
cases:6.81%
controls:0.40%
—
—
cases:1.86%
controls:0.00%
cases:18.35%
controls:0.00%
cases:29.35%
controls:0.38%
—
—
8
19
315
3209
22
13
301
3215
—
6
0
317
3228
40
0
178
3222
27
12
65
3138
—
Palliative care
Z51.5 [45547323]
Z51.5 [45547323]
—
3.1e+00
1.0e+50
1.0e+50
—
4.4e+00
—
—
—
cases:4.64%
controls:0.22%
cases:9.29%
controls:0.00%
cases:2.17%
controls:0.00%
—
—
cases:23.91%
controls:0.38%
—
—
—
15
7
308
3221
30
0
293
3228
7
0
316
3228
—
22
12
70
3138
—
Gas panel - Venous blood
24339-4 [3000991]
24339-4 [3000991]
9.5e-02
8.8e-01
2.7e+00
—
2.7e+00
2.1e+00
—
cases:2.79%
controls:2.54%
cases:3.10%
controls:1.30%
cases:2.79%
controls:0.19%
—
—
cases:2.75%
controls:0.19%
cases:8.70%
controls:1.21%
—
—
9
82
314
3146
10
42
313
3186
9
6
314
3222
—
6
6
212
3216
8
38
84
3112
—
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
UJD10 [2001304788]
3.2e-01
1.5e+00
3.6e+00
—
—
2.3e+00
—
cases:8.67%
controls:6.44%
cases:6.81%
controls:1.55%
cases:6.19%
controls:0.19%
—
—
—
—
cases:13.04%
controls:1.49%
—
—
28
208
295
3020
22
50
301
3178
20
6
303
3222
—
—
12
47
80
3103
—
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
6598-7 [3019800]
-7.0e-02
6.9e-01
3.1e+00
—
2.3e+00
1.2e+00
—
cases:14.86%
controls:15.77%
cases:13.00%
controls:6.97%
cases:13.62%
controls:0.68%
—
—
cases:6.88%
controls:0.74%
cases:19.57%
controls:6.76%
—
—
48
509
275
2719
42
225
281
3003
44
22
279
3206
—
15
24
203
3198
18
213
74
2937
—
Osmolality of Urine
2695-5 [3026782]
2695-5 [3026782]
2.1e-01
8.0e-01
2.9e+00
—
2.4e+00
1.9e+00
—
cases:9.60%
controls:7.93%
cases:6.50%
controls:3.04%
cases:6.19%
controls:0.37%
—
—
cases:3.67%
controls:0.34%
cases:15.22%
controls:2.51%
—
—
31
256
292
2972
21
98
302
3130
20
12
303
3216
—
8
11
210
3211
14
79
78
3071
—
loperamide oxide; oral
A07DA05 [21600648]
A07DA05 [21600648]
—
1.2e+00
—
—
3.3e+00
3.9e+00
—
—
—
cases:2.48%
controls:0.77%
—
—
—
—
cases:5.50%
controls:0.22%
cases:28.26%
controls:0.76%
—
—
—
8
25
315
3203
—
—
12
7
206
3215
26
24
66
3126
—
loperamide; oral
A07DA03 [21600646]
A07DA03 [21600646]
—
1.2e+00
—
—
3.3e+00
3.9e+00
—
—
—
cases:2.48%
controls:0.77%
—
—
—
—
cases:5.50%
controls:0.22%
cases:28.26%
controls:0.76%
—
—
—
8
25
315
3203
—
—
12
7
206
3215
26
24
66
3126
—
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Blood
47598-8 [3048816]
47598-8 [3048816]
5.4e-01
9.8e-01
2.6e+00
—
2.3e+00
2.3e+00
—
cases:4.02%
controls:2.39%
cases:4.33%
controls:1.67%
cases:3.10%
controls:0.25%
—
—
cases:2.75%
controls:0.28%
cases:15.22%
controls:1.84%
—
—
13
77
310
3151
14
54
309
3174
10
8
313
3220
—
6
9
212
3213
14
58
78
3092
—
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
51480-2 [3031040]
1.6e-02
8.4e-01
2.8e+00
—
2.3e+00
1.2e+00
—
cases:27.24%
controls:26.92%
cases:25.70%
controls:12.95%
cases:21.67%
controls:1.70%
—
—
cases:15.14%
controls:1.77%
cases:32.61%
controls:13.05%
—
—
88
869
235
2359
83
418
240
2810
70
55
253
3173
—
33
57
185
3165
30
411
62
2739
—
Coloscopy
UJF32 [2001305029]
UJF32 [2001305029]
7.2e-01
1.3e+00
3.0e+00
—
—
2.0e+00
—
cases:9.60%
controls:4.93%
cases:4.64%
controls:1.30%
cases:3.10%
controls:0.15%
—
—
—
—
cases:7.61%
controls:1.08%
—
—
31
159
292
3069
15
42
308
3186
10
5
313
3223
—
—
7
34
85
3116
—
oxycodone and naloxone; oral
N02AA55 [21604265]
N02AA55 [21604265]
-1.5e-01
5.2e-01
2.0e+00
—
2.9e+00
2.0e+00
—
cases:3.10%
controls:3.56%
cases:3.10%
controls:1.86%
cases:1.86%
controls:0.25%
—
—
cases:5.96%
controls:0.34%
cases:10.87%
controls:1.59%
—
—
10
115
313
3113
10
60
313
3168
6
8
317
3220
—
13
11
205
3211
10
50
82
3100
—
General Surgery
2 [38004447]
2 [38004447]
8.6e-02
8.8e-01
3.0e+00
—
2.9e+00
1.2e+00
—
cases:16.72%
controls:15.55%
cases:9.60%
controls:4.21%
cases:10.84%
controls:0.59%
—
—
cases:11.01%
controls:0.65%
cases:11.96%
controls:3.84%
—
—
54
502
269
2726
31
136
292
3092
35
19
288
3209
—
24
21
194
3201
11
121
81
3029
—
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
N02AX02 [21604298]
4.4e-01
1.1e+00
2.4e+00
—
3.2e+00
1.1e+00
—
cases:11.46%
controls:7.68%
cases:7.74%
controls:2.63%
cases:4.33%
controls:0.40%
—
—
cases:10.55%
controls:0.47%
cases:6.52%
controls:2.19%
—
—
37
248
286
2980
25
85
298
3143
14
13
309
3215
—
23
15
195
3207
6
69
86
3081
—
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
77397-8 [46236098]
3.2e-01
1.1e+00
3.5e+00
—
—
2.2e+00
—
cases:8.98%
controls:6.66%
cases:6.81%
controls:2.39%
cases:10.22%
controls:0.34%
—
—
—
—
cases:19.57%
controls:2.70%
—
—
29
215
294
3013
22
77
301
3151
33
11
290
3217
—
—
18
85
74
3065
—
Urea [Moles/volume] in Serum or Plasma
22664-7 [3020779]
22664-7 [3020779]
6.0e-01
7.3e-01
2.5e+00
—
2.5e+00
1.8e+00
—
cases:4.33%
controls:2.42%
cases:3.72%
controls:1.83%
cases:4.33%
controls:0.37%
—
—
cases:4.59%
controls:0.40%
cases:7.61%
controls:1.37%
—
—
14
78
309
3150
12
59
311
3169
14
12
309
3216
—
10
13
208
3209
7
43
85
3107
—
Internal Medicine
11 [38004456]
11 [38004456]
8.0e-02
5.6e-01
2.5e+00
—
2.4e+00
1.2e+00
—
cases:29.41%
controls:27.79%
cases:17.34%
controls:10.72%
cases:15.79%
controls:1.52%
—
—
cases:10.09%
controls:0.96%
cases:28.26%
controls:10.25%
—
—
95
897
228
2331
56
346
267
2882
51
49
272
3179
—
22
31
196
3191
26
323
66
2827
—
Normoblasts [#/volume] in Blood
715-3 [3021589]
715-3 [3021589]
2.2e-01
6.5e-01
2.4e+00
—
2.1e+00
1.5e+00
—
cases:16.41%
controls:13.57%
cases:19.20%
controls:11.00%
cases:20.74%
controls:2.39%
—
—
cases:16.06%
controls:2.27%
cases:39.13%
controls:12.03%
—
—
53
438
270
2790
62
355
261
2873
67
77
256
3151
—
35
73
183
3149
36
379
56
2771
—
Chloride [Moles/volume] in Serum or Plasma
2075-0 [3014576]
2075-0 [3014576]
7.4e-02
1.1e+00
3.2e+00
1.0e+50
—
2.3e+00
—
cases:3.10%
controls:2.88%
cases:6.50%
controls:2.20%
cases:5.26%
controls:0.22%
cases:1.55%
controls:0.00%
—
—
cases:13.04%
controls:1.49%
—
—
10
93
313
3135
21
71
302
3157
17
7
306
3221
5
0
318
3228
—
12
47
80
3103
—
enoxaparin; parenteral
B01AB05 [21600976]
B01AB05 [21600976]
3.1e-01
9.8e-01
2.7e+00
—
—
2.8e+00
—
cases:9.29%
controls:7.00%
cases:5.26%
controls:2.04%
cases:2.17%
controls:0.15%
—
—
—
—
cases:16.30%
controls:1.17%
—
—
30
226
293
3002
17
66
306
3162
7
5
316
3223
—
—
15
37
77
3113
—
Epithelial cells.squamous [#/volume] in Urine by Automated count
51486-9 [3029879]
51486-9 [3029879]
1.9e-01
1.1e+00
2.6e+00
—
2.6e+00
1.3e+00
—
cases:4.64%
controls:3.87%
cases:6.50%
controls:2.35%
cases:5.57%
controls:0.43%
—
—
cases:3.67%
controls:0.28%
cases:8.70%
controls:2.63%
—
—
15
125
308
3103
21
76
302
3152
18
14
305
3214
—
8
9
210
3213
8
83
84
3067
—
dexamethasone; oral, parenteral
H02AB02 [21602730]
H02AB02 [21602730]
7.1e-01
1.9e+00
—
—
—
4.4e+00
—
cases:4.02%
controls:2.01%
cases:4.33%
controls:0.68%
—
—
—
—
—
—
cases:42.39%
controls:0.92%
—
—
13
65
310
3163
14
22
309
3206
—
—
—
39
29
53
3121
—
Epithelial cells.non-squamous [#/volume] in Urine by Automated count
51485-1 [3030306]
51485-1 [3030306]
1.9e-01
9.8e-01
2.5e+00
—
2.7e+00
1.1e+00
—
cases:4.33%
controls:3.62%
cases:6.19%
controls:2.42%
cases:5.57%
controls:0.46%
—
—
cases:3.67%
controls:0.25%
cases:8.70%
controls:2.95%
—
—
14
117
309
3111
20
78
303
3150
18
15
305
3213
—
8
8
210
3214
8
93
84
3057
—
Pneumonia, unspecified
J18.9 [45601123]
J18.9 [45601123]
1.5e-02
1.6e+00
2.3e+00
1.0e+50
2.2e+00
—
—
cases:6.50%
controls:6.41%
cases:8.98%
controls:1.89%
cases:2.48%
controls:0.25%
cases:2.48%
controls:0.00%
cases:3.21%
controls:0.37%
—
—
—
—
21
207
302
3021
29
61
294
3167
8
8
315
3220
8
0
315
3228
7
12
211
3210
—
—
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
14979-9 [3018677]
6.4e-03
9.8e-01
3.9e+00
—
—
2.2e+00
—
cases:4.64%
controls:4.62%
cases:4.33%
controls:1.67%
cases:8.67%
controls:0.19%
—
—
—
—
cases:10.87%
controls:1.37%
—
—
15
149
308
3079
14
54
309
3174
28
6
295
3222
—
—
10
43
82
3107
—
pH of Venous blood
2746-6 [3012544]
2746-6 [3012544]
4.2e-01
4.8e-01
3.1e+00
—
3.0e+00
—
—
cases:4.64%
controls:3.10%
cases:3.41%
controls:2.14%
cases:4.64%
controls:0.22%
—
—
cases:4.13%
controls:0.22%
—
—
—
—
15
100
308
3128
11
69
312
3159
15
7
308
3221
—
9
7
209
3215
—
—
Cancer Ag 125 [Units/volume] in Serum or Plasma
10334-1 [3037551]
10334-1 [3037551]
8.9e-01
2.5e+00
—
—
—
3.6e+00
—
cases:1.86%
controls:0.77%
cases:5.57%
controls:0.50%
—
—
—
—
—
—
cases:8.70%
controls:0.25%
—
—
6
25
317
3203
18
16
305
3212
—
—
—
8
8
84
3142
—
More than one and less than three hours
ZXE10 [2001311401]
ZXE10 [2001311401]
2.9e-01
1.2e+00
2.5e+00
—
—
2.4e+00
—
cases:8.36%
controls:6.41%
cases:4.02%
controls:1.27%
cases:1.86%
controls:0.15%
—
—
—
—
cases:6.52%
controls:0.63%
—
—
27
207
296
3021
13
41
310
3187
6
5
317
3223
—
—
6
20
86
3130
—
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
14879-1 [3003458]
6.4e-01
7.3e-01
2.2e+00
—
2.3e+00
1.6e+00
—
cases:6.19%
controls:3.38%
cases:4.64%
controls:2.29%
cases:4.64%
controls:0.53%
—
—
cases:4.59%
controls:0.50%
cases:9.78%
controls:2.19%
—
—
20
109
303
3119
15
74
308
3154
15
17
308
3211
—
10
16
208
3206
9
69
83
3081
—
Microorganisms panel - Urine sediment
58435-9 [40761536]
58435-9 [40761536]
2.5e-01
1.5e+00
2.6e+00
—
—
2.0e+00
—
cases:4.64%
controls:3.66%
cases:5.26%
controls:1.24%
cases:2.79%
controls:0.22%
—
—
—
—
cases:8.70%
controls:1.30%
—
—
15
118
308
3110
17
40
306
3188
9
7
314
3221
—
—
8
41
84
3109
—
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
24357-6 [3037467]
-8.6e-04
7.0e-01
2.4e+00
—
1.8e+00
1.1e+00
—
cases:28.17%
controls:28.19%
cases:24.77%
controls:14.00%
cases:17.03%
controls:1.86%
—
—
cases:9.63%
controls:1.68%
cases:30.43%
controls:12.79%
—
—
91
910
232
2318
80
452
243
2776
55
60
268
3168
—
21
54
197
3168
28
403
64
2747
—
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
34487-9 [3044938]
4.3e-01
1.0e+00
2.5e+00
—
2.4e+00
1.2e+00
—
cases:6.19%
controls:4.12%
cases:6.50%
controls:2.42%
cases:3.72%
controls:0.31%
—
—
cases:4.13%
controls:0.37%
cases:8.70%
controls:2.92%
—
—
20
133
303
3095
21
78
302
3150
12
10
311
3218
—
9
12
209
3210
8
92
84
3058
—
Base excess in Venous blood by calculation
1927-3 [3002032]
1927-3 [3002032]
4.9e-01
6.0e-01
3.1e+00
—
2.9e+00
1.1e+00
—
cases:4.95%
controls:3.10%
cases:3.72%
controls:2.08%
cases:4.64%
controls:0.22%
—
—
cases:3.67%
controls:0.22%
cases:5.43%
controls:1.84%
—
—
16
100
307
3128
12
67
311
3161
15
7
308
3221
—
8
7
210
3215
5
58
87
3092
—
Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]
2021-4 [3021447]
3.5e-01
5.4e-01
3.1e+00
—
2.9e+00
1.1e+00
—
cases:4.33%
controls:3.10%
cases:3.72%
controls:2.20%
cases:4.64%
controls:0.22%
—
—
cases:3.67%
controls:0.22%
cases:5.43%
controls:1.84%
—
—
14
100
309
3128
12
71
311
3157
15
7
308
3221
—
8
7
210
3215
5
58
87
3092
—
Essential (primary) hypertension
I10 [45591453]
I10 [45591453]
2.1e-01
3.7e-02
1.4e+00
3.3e+00
1.3e+00
3.8e-02
—
cases:37.15%
controls:32.47%
cases:15.79%
controls:15.30%
cases:10.22%
controls:2.82%
cases:5.57%
controls:0.22%
cases:10.55%
controls:3.17%
cases:17.39%
controls:16.86%
—
—
120
1048
203
2180
51
494
272
2734
33
91
290
3137
18
7
305
3221
23
102
195
3120
16
531
76
2619
—
Bacteria identified in Isolate by Culture
43409-2 [3042936]
43409-2 [3042936]
2.0e-01
1.1e+00
—
1.0e+50
3.1e+00
1.7e+00
—
cases:4.95%
controls:4.09%
cases:4.64%
controls:1.55%
—
—
cases:3.41%
controls:0.00%
cases:3.21%
controls:0.16%
cases:7.61%
controls:1.43%
—
—
16
132
307
3096
15
50
308
3178
—
11
0
312
3228
7
5
211
3217
7
45
85
3105
—
Abdominal ultrasound examination
JN3AE [2001305555]
JN3AE [2001305555]
5.9e-01
2.2e+00
—
—
—
3.6e+00
—
cases:3.10%
controls:1.73%
cases:2.48%
controls:0.28%
—
—
—
—
—
—
cases:10.87%
controls:0.32%
—
—
10
56
313
3172
8
9
315
3219
—
—
—
10
10
82
3140
—
Office Visit
OMOP4822458 [581477]
OMOP4822458 [581477]
1.6e-01
1.2e+00
—
—
2.7e+00
1.8e+00
—
cases:12.38%
controls:10.72%
cases:6.50%
controls:1.98%
—
—
—
—
cases:2.75%
controls:0.19%
cases:8.70%
controls:1.56%
—
—
40
346
283
2882
21
64
302
3164
—
—
6
6
212
3216
8
49
84
3101
—
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
5802-4 [3021601]
-8.3e-02
6.9e-01
2.1e+00
—
2.0e+00
8.8e-01
—
cases:16.10%
controls:17.26%
cases:16.10%
controls:8.77%
cases:9.60%
controls:1.24%
—
—
cases:7.34%
controls:1.09%
cases:21.74%
controls:10.35%
—
—
52
557
271
2671
52
283
271
2945
31
40
292
3188
—
16
35
202
3187
20
326
72
2824
—
Obstetrics / Gynecology
16 [38004461]
16 [38004461]
-5.7e-03
3.0e-01
2.8e+00
—
2.8e+00
1.3e+00
—
cases:6.50%
controls:6.54%
cases:3.41%
controls:2.54%
cases:5.57%
controls:0.37%
—
—
cases:4.59%
controls:0.28%
cases:7.61%
controls:2.13%
—
—
21
211
302
3017
11
82
312
3146
18
12
305
3216
—
10
9
208
3213
7
67
85
3083
—
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
14798-3 [3022948]
7.1e-01
1.1e+00
2.5e+00
—
2.0e+00
1.0e+00
—
cases:8.36%
controls:4.31%
cases:6.81%
controls:2.35%
cases:4.02%
controls:0.34%
—
—
cases:3.21%
controls:0.47%
cases:7.61%
controls:2.92%
—
—
27
139
296
3089
22
76
301
3152
13
11
310
3217
—
7
15
211
3207
7
92
85
3058
—
Urate [Moles/volume] in Serum or Plasma
14933-6 [3026493]
14933-6 [3026493]
2.1e-01
6.3e-01
2.8e+00
—
2.7e+00
7.9e-01
—
cases:11.46%
controls:9.45%
cases:6.50%
controls:3.56%
cases:3.10%
controls:0.19%
—
—
cases:4.13%
controls:0.28%
cases:7.61%
controls:3.59%
—
—
37
305
286
2923
21
115
302
3113
10
6
313
3222
—
9
9
209
3213
7
113
85
3037
—
Bacteria identified in Urine by Culture
630-4 [3026008]
630-4 [3026008]
2.4e-01
6.9e-01
2.4e+00
—
2.2e+00
8.7e-01
—
cases:13.62%
controls:11.03%
cases:11.15%
controls:5.92%
cases:8.05%
controls:0.77%
—
—
cases:6.42%
controls:0.74%
cases:13.04%
controls:5.90%
—
—
44
356
279
2872
36
191
287
3037
26
25
297
3203
—
14
24
204
3198
12
186
80
2964
—
Teaching
WZC30 [2001310891]
WZC30 [2001310891]
6.7e-01
1.6e+00
—
1.0e+50
—
3.7e+00
—
cases:4.02%
controls:2.11%
cases:4.02%
controls:0.87%
—
—
cases:2.79%
controls:0.00%
—
—
cases:21.74%
controls:0.67%
—
—
13
68
310
3160
13
28
310
3200
—
9
0
314
3228
—
20
21
72
3129
—
Immunohistochemistry procedure
117617002 [4035726]
117617002 [4035726]
1.9e+00
3.4e+00
—
1.0e+50
1.0e+50
—
—
cases:3.41%
controls:0.53%
cases:4.33%
controls:0.15%
—
—
cases:21.36%
controls:0.00%
cases:7.34%
controls:0.00%
—
—
—
—
11
17
312
3211
14
5
309
3223
—
69
0
254
3228
16
0
202
3222
—
—
12 lead EKG panel
34534-8 [3044889]
34534-8 [3044889]
6.0e-02
1.4e-01
1.9e+00
—
2.2e+00
1.0e+00
—
cases:33.44%
controls:32.13%
cases:17.34%
controls:15.40%
cases:11.46%
controls:1.86%
—
—
cases:17.43%
controls:2.23%
cases:32.61%
controls:14.57%
—
—
108
1037
215
2191
56
497
267
2731
37
60
286
3168
—
38
72
180
3150
30
459
62
2691
—
Sodium and Potassium panel [Moles/volume] - Serum or Plasma
34548-8 [3045783]
34548-8 [3045783]
-3.3e-01
-1.7e-01
2.2e+00
—
3.0e+00
—
—
cases:4.95%
controls:6.75%
cases:2.48%
controls:2.91%
cases:3.72%
controls:0.43%
—
—
cases:4.59%
controls:0.25%
—
—
—
—
16
218
307
3010
8
94
315
3134
12
14
311
3214
—
10
8
208
3214
—
—
ABO and Rh group [Type] in Blood
882-1 [3003694]
882-1 [3003694]
1.7e-01
7.3e-01
—
—
3.3e+00
1.8e+00
—
cases:6.81%
controls:5.82%
cases:4.02%
controls:1.98%
—
—
—
—
cases:4.13%
controls:0.16%
cases:8.70%
controls:1.62%
—
—
22
188
301
3040
13
64
310
3164
—
—
9
5
209
3217
8
51
84
3099
—
Removal of sutures
SPAT1153 [2001700254]
SPAT1153 [2001700254]
4.5e-01
9.3e-02
—
—
2.9e+00
2.2e+00
—
cases:12.69%
controls:8.49%
cases:2.48%
controls:2.26%
—
—
—
—
cases:2.75%
controls:0.16%
cases:10.87%
controls:1.40%
—
—
41
274
282
2954
8
73
315
3155
—
—
6
5
212
3217
10
44
82
3106
—
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
2703-7 [3027801]
-5.4e-01
7.6e-01
2.7e+00
1.0e+50
—
2.4e+00
—
cases:2.17%
controls:3.66%
cases:3.72%
controls:1.77%
cases:2.17%
controls:0.15%
cases:2.17%
controls:0.00%
—
—
cases:10.87%
controls:1.14%
—
—
7
118
316
3110
12
57
311
3171
7
5
316
3223
7
0
316
3228
—
10
36
82
3114
—
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
2019-8 [3027946]
-5.4e-01
7.5e-01
2.7e+00
1.0e+50
—
2.4e+00
—
cases:2.17%
controls:3.66%
cases:3.72%
controls:1.80%
cases:2.17%
controls:0.15%
cases:2.17%
controls:0.00%
—
—
cases:10.87%
controls:1.14%
—
—
7
118
316
3110
12
58
311
3170
7
5
316
3223
7
0
316
3228
—
10
36
82
3114
—
Base excess in Arterial blood by calculation
1925-7 [3003396]
1925-7 [3003396]
-5.2e-01
7.5e-01
2.7e+00
1.0e+50
—
2.3e+00
—
cases:2.17%
controls:3.59%
cases:3.72%
controls:1.80%
cases:2.17%
controls:0.15%
cases:2.17%
controls:0.00%
—
—
cases:9.78%
controls:1.11%
—
—
7
116
316
3112
12
58
311
3170
7
5
316
3223
7
0
316
3228
—
9
35
83
3115
—
pH of Arterial blood
2744-1 [3019977]
2744-1 [3019977]
-5.3e-01
8.5e-01
2.5e+00
1.0e+50
—
2.4e+00
—
cases:2.17%
controls:3.62%
cases:4.02%
controls:1.77%
cases:1.86%
controls:0.15%
cases:2.17%
controls:0.00%
—
—
cases:10.87%
controls:1.08%
—
—
7
117
316
3111
13
57
310
3171
6
5
317
3223
7
0
316
3228
—
10
34
82
3116
—
Lactate [Moles/volume] in Serum or Plasma
2524-7 [3014111]
2524-7 [3014111]
-3.8e-02
6.4e-01
2.8e+00
—
—
2.0e+00
—
cases:2.48%
controls:2.57%
cases:2.79%
controls:1.49%
cases:3.10%
controls:0.19%
—
—
—
—
cases:7.61%
controls:1.05%
—
—
8
83
315
3145
9
48
314
3180
10
6
313
3222
—
—
7
33
85
3117
—
EKG study
11524-6 [3013512]
11524-6 [3013512]
-5.4e-02
2.2e-01
2.6e+00
—
2.3e+00
6.1e-01
—
cases:13.00%
controls:13.63%
cases:9.29%
controls:7.62%
cases:7.43%
controls:0.62%
—
—
cases:7.34%
controls:0.78%
cases:13.04%
controls:7.56%
—
—
42
440
281
2788
30
246
293
2982
24
20
299
3208
—
16
25
202
3197
12
238
80
2912
—
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
53292-9 [3041096]
7.4e-02
1.0e+00
2.5e+00
—
1.4e+00
1.3e+00
—
cases:10.53%
controls:9.85%
cases:11.46%
controls:4.34%
cases:6.19%
controls:0.53%
—
—
cases:2.29%
controls:0.59%
cases:14.13%
controls:4.44%
—
—
34
318
289
2910
37
140
286
3088
20
17
303
3211
—
5
19
213
3203
13
140
79
3010
—
Case Management Agency
251B00000X [38004193]
251B00000X [38004193]
-3.7e-02
4.7e-02
1.3e+00
2.2e+00
1.3e+00
1.0e+00
—
cases:81.73%
controls:82.28%
cases:75.23%
controls:74.35%
cases:62.54%
controls:30.70%
cases:16.72%
controls:2.17%
cases:62.39%
controls:31.63%
cases:90.22%
controls:76.44%
—
—
264
2656
59
572
243
2400
80
828
202
991
121
2237
54
70
269
3158
136
1019
82
2203
83
2408
9
742
—
pantoprazole; oral, parenteral
A02BC02 [21600097]
A02BC02 [21600097]
-5.0e-02
5.6e-01
9.3e-01
—
1.7e+00
1.6e+00
—
cases:24.77%
controls:25.71%
cases:24.15%
controls:15.37%
cases:9.60%
controls:4.03%
—
—
cases:18.81%
controls:3.91%
cases:47.83%
controls:15.97%
—
—
80
830
243
2398
78
496
245
2732
31
130
292
3098
—
41
126
177
3096
44
503
48
2647
—
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
25428-4 [3009261]
-1.0e-01
6.6e-01
2.2e+00
—
1.9e+00
8.5e-01
—
cases:16.41%
controls:17.84%
cases:16.41%
controls:9.20%
cases:10.53%
controls:1.30%
—
—
cases:7.34%
controls:1.12%
cases:21.74%
controls:10.57%
—
—
53
576
270
2652
53
297
270
2931
34
42
289
3186
—
16
36
202
3186
20
333
72
2817
—
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
2514-8 [3035350]
-8.0e-02
6.3e-01
2.2e+00
—
2.0e+00
8.6e-01
—
cases:16.41%
controls:17.53%
cases:15.79%
controls:9.08%
cases:10.22%
controls:1.27%
—
—
cases:7.34%
controls:1.09%
cases:21.74%
controls:10.48%
—
—
53
566
270
2662
51
293
272
2935
33
41
290
3187
—
16
35
202
3187
20
330
72
2820
—
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
50949-7 [3029937]
-1.2e-01
6.7e-01
2.6e+00
—
2.1e+00
9.1e-01
—
cases:10.22%
controls:11.34%
cases:10.22%
controls:5.51%
cases:7.12%
controls:0.56%
—
—
cases:4.59%
controls:0.56%
cases:13.04%
controls:5.68%
—
—
33
366
290
2862
33
178
290
3050
23
18
300
3210
—
10
18
208
3204
12
179
80
2971
—
Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection
54067-4 [3051552]
54067-4 [3051552]
-6.3e-04
—
2.6e+00
—
—
2.2e+00
—
cases:1.86%
controls:1.86%
—
—
cases:2.79%
controls:0.22%
—
—
—
—
cases:6.52%
controls:0.79%
—
—
6
60
317
3168
—
9
7
314
3221
—
—
6
25
86
3125
—
Chronic kidney disease, unspecified
N18.9 [45553438]
N18.9 [45553438]
5.2e-02
8.3e-01
2.5e+00
—
2.3e+00
-1.0e+50
—
cases:1.86%
controls:1.77%
cases:2.17%
controls:0.96%
cases:2.48%
controls:0.22%
—
—
cases:3.21%
controls:0.34%
cases:0.00%
controls:1.30%
—
—
6
57
317
3171
7
31
316
3197
8
7
315
3221
—
7
11
211
3211
0
41
92
3109
—
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
13317-3 [3019902]
4.2e-01
7.5e-01
2.8e+00
—
—
1.8e+00
—
cases:5.57%
controls:3.72%
cases:3.72%
controls:1.80%
cases:4.02%
controls:0.25%
—
—
—
—
cases:8.70%
controls:1.52%
—
—
18
120
305
3108
12
58
311
3170
13
8
310
3220
—
—
8
48
84
3102
—
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
4537-7 [3013707]
-1.5e-02
5.4e-01
2.6e+00
—
1.5e+00
-1.0e-01
—
cases:30.96%
controls:31.29%
cases:22.91%
controls:14.75%
cases:19.20%
controls:1.70%
—
—
cases:5.96%
controls:1.43%
cases:11.96%
controls:13.05%
—
—
100
1010
223
2218
74
476
249
2752
62
55
261
3173
—
13
46
205
3176
11
411
81
2739
—
Bacterial infection, unspecified
A49.9 [45590816]
A49.9 [45590816]
7.9e-01
1.9e+00
—
—
—
2.7e+00
—
cases:4.02%
controls:1.86%
cases:4.33%
controls:0.65%
—
—
—
—
—
—
cases:10.87%
controls:0.83%
—
—
13
60
310
3168
14
21
309
3207
—
—
—
10
26
82
3124
—
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
60026-2 [40763086]
-1.6e-01
6.7e-01
2.3e+00
—
1.7e+00
9.4e-01
—
cases:13.62%
controls:15.61%
cases:13.62%
controls:7.43%
cases:7.74%
controls:0.87%
—
—
cases:4.59%
controls:0.90%
cases:17.39%
controls:7.59%
—
—
44
504
279
2724
44
240
279
2988
25
28
298
3200
—
10
29
208
3193
16
239
76
2911
—
Fever, unspecified
R50.9 [45582716]
R50.9 [45582716]
3.1e-01
1.8e+00
—
—
—
2.8e+00
—
cases:2.48%
controls:1.83%
cases:2.79%
controls:0.46%
—
—
—
—
—
—
cases:9.78%
controls:0.67%
—
—
8
59
315
3169
9
15
314
3213
—
—
—
9
21
83
3129
—
Bilirubin.conjugated [Moles/volume] in Serum or Plasma
29760-6 [3005772]
29760-6 [3005772]
3.6e-01
1.9e+00
—
—
—
2.6e+00
—
cases:4.33%
controls:3.07%
cases:5.88%
controls:0.90%
—
—
—
—
—
—
cases:10.87%
controls:0.92%
—
—
14
99
309
3129
19
29
304
3199
—
—
—
10
29
82
3121
—
Malaise and fatigue
R53 [45553741]
R53 [45553741]
-2.4e-01
9.3e-01
2.3e+00
—
2.1e+00
1.4e+00
—
cases:4.33%
controls:5.45%
cases:4.64%
controls:1.89%
cases:4.02%
controls:0.40%
—
—
cases:2.75%
controls:0.34%
cases:9.78%
controls:2.70%
—
—
14
176
309
3052
15
61
308
3167
13
13
310
3215
—
6
11
212
3211
9
85
83
3065
—
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
2157-6 [3007220]
-6.2e-02
3.7e-01
2.3e+00
—
2.2e+00
1.1e+00
—
cases:10.53%
controls:11.12%
cases:5.57%
controls:3.93%
cases:4.02%
controls:0.43%
—
—
cases:3.21%
controls:0.37%
cases:10.87%
controls:3.97%
—
—
34
359
289
2869
18
127
305
3101
13
14
310
3214
—
7
12
211
3210
10
125
82
3025
—
Abdominal CT examination
JN3AD [2001305554]
JN3AD [2001305554]
1.0e+00
2.3e+00
—
—
1.0e+50
2.1e+00
—
cases:2.17%
controls:0.77%
cases:4.64%
controls:0.50%
—
—
—
—
cases:2.29%
controls:0.00%
cases:5.43%
controls:0.67%
—
—
7
25
316
3203
15
16
308
3212
—
—
5
0
213
3222
5
21
87
3129
—
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
3034-6 [3004789]
8.3e-01
1.2e+00
2.4e+00
—
—
1.1e+00
—
cases:7.74%
controls:3.53%
cases:6.50%
controls:2.14%
cases:3.41%
controls:0.31%
—
—
—
—
cases:7.61%
controls:2.79%
—
—
25
114
298
3114
21
69
302
3159
11
10
312
3218
—
—
7
88
85
3062
—
Hemoglobin [Presence] in Urine by Test strip
5794-3 [3011397]
5794-3 [3011397]
-1.8e-01
2.8e-01
1.9e+00
—
2.5e+00
3.7e-01
—
cases:6.50%
controls:7.65%
cases:5.57%
controls:4.28%
cases:4.02%
controls:0.62%
—
—
cases:5.05%
controls:0.43%
cases:7.61%
controls:5.40%
—
—
21
247
302
2981
18
138
305
3090
13
20
310
3208
—
11
14
207
3208
7
170
85
2980
—
pH of Urine
2756-5 [3015736]
2756-5 [3015736]
1.3e-01
6.2e-01
2.2e+00
—
2.2e+00
5.1e-01
—
cases:15.79%
controls:14.19%
cases:11.76%
controls:6.72%
cases:7.12%
controls:0.87%
—
—
cases:5.96%
controls:0.71%
cases:11.96%
controls:7.52%
—
—
51
458
272
2770
38
217
285
3011
23
28
300
3200
—
13
23
205
3199
11
237
81
2913
—
Prostate specific Ag [Mass/volume] in Serum or Plasma
2857-1 [3013603]
2857-1 [3013603]
-4.1e-02
2.4e-01
1.9e+00
—
2.3e+00
1.6e-01
—
cases:18.89%
controls:19.52%
cases:12.07%
controls:9.76%
cases:8.36%
controls:1.33%
—
—
cases:7.34%
controls:0.81%
cases:11.96%
controls:10.41%
—
—
61
630
262
2598
39
315
284
2913
27
43
296
3185
—
16
26
202
3196
11
328
81
2822
—
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
57782-5 [40760892]
1.0e-01
3.3e-01
2.2e+00
—
2.0e+00
7.9e-01
—
cases:6.81%
controls:6.20%
cases:4.64%
controls:3.38%
cases:4.64%
controls:0.53%
—
—
cases:3.21%
controls:0.47%
cases:6.52%
controls:3.08%
—
—
22
200
301
3028
15
109
308
3119
15
17
308
3211
—
7
15
211
3207
6
97
86
3053
—
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
68438-1 [40771025]
9.4e-02
5.4e-01
2.1e+00
—
2.1e+00
5.7e-01
—
cases:13.31%
controls:12.27%
cases:11.15%
controls:6.82%
cases:4.33%
controls:0.56%
—
—
cases:5.96%
controls:0.81%
cases:11.96%
controls:7.11%
—
—
43
396
280
2832
36
220
287
3008
14
18
309
3210
—
13
26
205
3196
11
224
81
2926
—
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
14804-9 [3022250]
6.0e-01
1.3e+00
—
—
—
2.8e+00
—
cases:4.33%
controls:2.42%
cases:4.33%
controls:1.18%
—
—
—
—
—
—
cases:14.13%
controls:1.02%
—
—
14
78
309
3150
14
38
309
3190
—
—
—
13
32
79
3118
—
Specific gravity of Urine by Refractometry
5810-7 [3019150]
5810-7 [3019150]
-2.4e-01
3.1e-01
2.2e+00
—
1.9e+00
7.8e-02
—
cases:7.43%
controls:9.26%
cases:6.50%
controls:4.83%
cases:4.33%
controls:0.50%
—
—
cases:3.21%
controls:0.50%
cases:5.43%
controls:5.05%
—
—
24
299
299
2929
21
156
302
3072
14
16
309
3212
—
7
16
211
3206
5
159
87
2991
—
Alpha-1-Fetoprotein [Units/volume] in Serum or Plasma
19176-7 [3015916]
19176-7 [3015916]
-1.0e+50
—
—
—
1.0e+50
4.1e+00
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
cases:5.05%
controls:0.00%
cases:8.70%
controls:0.16%
—
—
0
11
323
3217
—
—
—
11
0
207
3222
8
5
84
3145
—
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
33762-6 [3029187]
1.3e-01
7.2e-01
2.1e+00
—
1.4e+00
1.3e+00
—
cases:12.69%
controls:11.37%
cases:12.38%
controls:6.41%
cases:6.19%
controls:0.81%
—
—
cases:3.67%
controls:0.90%
cases:20.65%
controls:6.92%
—
—
41
367
282
2861
40
207
283
3021
20
26
303
3202
—
8
29
210
3193
19
218
73
2932
—
Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma
12841-3 [3001784]
12841-3 [3001784]
-4.8e-02
2.2e-01
1.8e+00
—
2.0e+00
-1.8e-02
—
cases:14.24%
controls:14.84%
cases:8.67%
controls:7.09%
cases:4.64%
controls:0.77%
—
—
cases:4.59%
controls:0.62%
cases:6.52%
controls:6.63%
—
—
46
479
277
2749
28
229
295
2999
15
25
308
3203
—
10
20
208
3202
6
209
86
2941
—
Stomach Pathology biopsy report
66114-0 [40768797]
66114-0 [40768797]
2.4e-01
1.6e+00
—
—
—
2.2e+00
—
cases:5.26%
controls:4.18%
cases:4.02%
controls:0.81%
—
—
—
—
—
—
cases:6.52%
controls:0.79%
—
—
17
135
306
3093
13
26
310
3202
—
—
—
6
25
86
3125
—
Blood transfusion
WW500 [2001310603]
WW500 [2001310603]
—
—
—
—
—
3.8e+00
—
—
—
—
—
—
—
—
—
—
—
cases:7.61%
controls:0.19%
—
—
—
—
—
—
—
7
6
85
3144
—
lorazepam; oral, parenteral, sublingual
N05BA06 [21604571]
N05BA06 [21604571]
1.1e-01
1.2e+00
—
—
—
2.5e+00
—
cases:1.55%
controls:1.39%
cases:3.72%
controls:1.12%
—
—
—
—
—
—
cases:10.87%
controls:0.98%
—
—
5
45
318
3183
12
36
311
3192
—
—
—
10
31
82
3119
—
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
J01MA12 [21603019]
2.4e-01
1.5e+00
—
—
—
2.2e+00
—
cases:3.72%
controls:2.94%
cases:2.79%
controls:0.65%
—
—
—
—
—
—
cases:7.61%
controls:0.89%
—
—
12
95
311
3133
9
21
314
3207
—
—
—
7
28
85
3122
—
One hour or less
ZXE00 [2001311394]
ZXE00 [2001311394]
1.1e-01
1.0e+00
—
—
—
2.7e+00
—
cases:8.05%
controls:7.25%
cases:4.64%
controls:1.77%
—
—
—
—
—
—
cases:13.04%
controls:1.02%
—
—
26
234
297
2994
15
57
308
3171
—
—
—
12
32
80
3118
—
Intravenous
ZX120 [2001311495]
ZX120 [2001311495]
9.6e-01
—
—
—
—
3.6e+00
—
cases:2.48%
controls:0.96%
—
—
—
—
—
—
—
—
cases:10.87%
controls:0.32%
—
—
8
31
315
3197
—
—
—
—
10
10
82
3140
—
Scheduled procedure
ZXD10 [2001311387]
ZXD10 [2001311387]
6.7e-02
1.2e+00
—
—
—
2.3e+00
—
cases:7.12%
controls:6.69%
cases:3.72%
controls:1.12%
—
—
—
—
—
—
cases:6.52%
controls:0.67%
—
—
23
216
300
3012
12
36
311
3192
—
—
—
6
21
86
3129
—
Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]
60517-0 [40763571]
7.5e-01
1.2e+00
2.3e+00
—
—
1.1e+00
—
cases:7.12%
controls:3.50%
cases:6.19%
controls:1.98%
cases:3.10%
controls:0.31%
—
—
—
—
cases:7.61%
controls:2.63%
—
—
23
113
300
3115
20
64
303
3164
10
10
313
3218
—
—
7
83
85
3067
—
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]
30248-9 [3015399]
2.8e-01
1.1e+00
2.3e+00
—
—
1.1e+00
—
cases:11.15%
controls:8.64%
cases:12.07%
controls:4.18%
cases:4.02%
controls:0.40%
—
—
—
—
cases:10.87%
controls:3.78%
—
—
36
279
287
2949
39
135
284
3093
13
13
310
3215
—
—
10
119
82
3031
—
Type 2 diabetes mellitus, without complications
E11.9 [45561952]
E11.9 [45561952]
3.1e-01
3.8e-01
1.9e+00
—
1.6e+00
5.8e-01
—
cases:13.31%
controls:10.13%
cases:7.12%
controls:4.99%
cases:5.26%
controls:0.84%
—
—
cases:5.05%
controls:1.09%
cases:8.70%
controls:5.08%
—
—
43
327
280
2901
23
161
300
3067
17
27
306
3201
—
11
35
207
3187
8
160
84
2990
—
Protein [Mass/volume] in Urine
2888-6 [3037121]
2888-6 [3037121]
3.9e-01
—
—
—
—
3.4e+00
—
cases:1.86%
controls:1.27%
—
—
—
—
—
—
—
—
cases:7.61%
controls:0.29%
—
—
6
41
317
3187
—
—
—
—
7
9
85
3141
—
Home Visit
OMOP4822459 [581476]
OMOP4822459 [581476]
3.4e-01
5.7e-01
8.8e-01
2.6e-01
1.3e+00
1.1e+00
—
cases:17.03%
controls:12.73%
cases:14.55%
controls:8.80%
cases:8.05%
controls:3.50%
cases:2.17%
controls:1.67%
cases:13.30%
controls:3.85%
cases:26.09%
controls:10.29%
—
—
55
411
268
2817
47
284
276
2944
26
113
297
3115
7
54
316
3174
29
124
189
3098
24
324
68
2826
—
Pulmonary Disease
29 [38004472]
29 [38004472]
4.0e-01
8.2e-01
1.2e+00
—
1.3e+00
5.9e-01
—
cases:17.03%
controls:12.05%
cases:13.31%
controls:6.35%
cases:5.57%
controls:1.70%
—
—
cases:5.05%
controls:1.43%
cases:10.87%
controls:6.35%
—
—
55
389
268
2839
43
205
280
3023
18
55
305
3173
—
11
46
207
3176
10
200
82
2950
—
Extensive CT examination of arteria pulmonalis
FB1BD [2001302407]
FB1BD [2001302407]
—
1.7e+00
—
—
—
3.3e+00
—
—
—
cases:1.86%
controls:0.34%
—
—
—
—
—
—
cases:6.52%
controls:0.25%
—
—
—
6
11
317
3217
—
—
—
6
8
86
3142
—
General anesthesia, balanced
WX408 [2001310808]
WX408 [2001310808]
4.1e-01
1.0e+00
—
—
—
3.2e+00
—
cases:7.12%
controls:4.83%
cases:2.17%
controls:0.81%
—
—
—
—
—
—
cases:7.61%
controls:0.32%
—
—
23
156
300
3072
7
26
316
3202
—
—
—
7
10
85
3140
—
Urology
34 [38004474]
34 [38004474]
3.3e-01
9.9e-01
2.2e+00
—
—
8.5e-01
—
cases:10.84%
controls:8.02%
cases:6.81%
controls:2.63%
cases:2.79%
controls:0.31%
—
—
—
—
cases:6.52%
controls:2.89%
—
—
35
259
288
2969
22
85
301
3143
9
10
314
3218
—
—
6
91
86
3059
—
Bicarbonate [Moles/volume] standard in Venous blood
19232-8 [3007628]
19232-8 [3007628]
4.0e-01
1.1e+00
3.2e+00
—
—
—
—
cases:2.17%
controls:1.46%
cases:2.79%
controls:0.93%
cases:3.72%
controls:0.15%
—
—
—
—
—
—
—
—
7
47
316
3181
9
30
314
3198
12
5
311
3223
—
—
—
—
Pulmonary embolism without mention of acute cor pulmonale
I26.9 [45552785]
I26.9 [45552785]
9.3e-01
—
—
—
—
3.2e+00
—
cases:1.86%
controls:0.74%
—
—
—
—
—
—
—
—
cases:9.78%
controls:0.44%
—
—
6
24
317
3204
—
—
—
—
9
14
83
3136
—
Folate [Moles/volume] in Serum or Plasma
14732-2 [3021960]
14732-2 [3021960]
-6.5e-04
4.1e-01
1.9e+00
—
—
1.2e+00
—
cases:5.26%
controls:5.27%
cases:6.50%
controls:4.43%
cases:2.48%
controls:0.37%
—
—
—
—
cases:16.30%
controls:5.40%
—
—
17
170
306
3058
21
143
302
3085
8
12
315
3216
—
—
15
170
77
2980
—
Laceration/cut
S18 [2002000983]
S18 [2002000983]
4.0e-01
5.3e-01
-1.0e+50
—
1.9e+00
1.2e+00
—
cases:17.03%
controls:12.14%
cases:7.12%
controls:4.34%
cases:0.00%
controls:0.53%
—
—
cases:3.67%
controls:0.59%
cases:13.04%
controls:4.25%
—
—
55
392
268
2836
23
140
300
3088
0
17
323
3211
—
8
19
210
3203
12
134
80
3016
—
Oxygen [Partial pressure] in Venous blood
2705-2 [3024354]
2705-2 [3024354]
2.4e-01
4.1e-01
3.0e+00
—
—
—
—
cases:3.10%
controls:2.45%
cases:2.79%
controls:1.86%
cases:3.10%
controls:0.15%
—
—
—
—
—
—
—
—
10
79
313
3149
9
60
314
3168
10
5
313
3223
—
—
—
—
Intravenous administration of medicine
SPAT1255 [2001700356]
SPAT1255 [2001700356]
6.5e-01
1.4e+00
—
—
—
3.0e+00
—
cases:2.17%
controls:1.15%
cases:1.86%
controls:0.46%
—
—
—
—
—
—
cases:7.61%
controls:0.41%
—
—
7
37
316
3191
6
15
317
3213
—
—
—
7
13
85
3137
—
Oxygen capacity [Volume Fraction] in Arterial blood
59275-8 [40762366]
59275-8 [40762366]
—
1.5e+00
—
—
—
2.9e+00
—
—
—
cases:2.48%
controls:0.56%
—
—
—
—
—
—
cases:7.61%
controls:0.44%
—
—
—
8
18
315
3210
—
—
—
7
14
85
3136
—
Supine thorax X-ray examination
GD1QA [2001303648]
GD1QA [2001303648]
-7.6e-02
3.2e-01
2.9e+00
—
—
1.4e+00
—
cases:3.72%
controls:4.00%
cases:3.10%
controls:2.26%
cases:3.72%
controls:0.22%
—
—
—
—
cases:6.52%
controls:1.68%
—
—
12
129
311
3099
10
73
313
3155
12
7
311
3221
—
—
6
53
86
3097
—
Creatine kinase.MB [Mass/volume] in Serum or Plasma
13969-1 [3005785]
13969-1 [3005785]
-3.8e-02
-2.1e-02
2.8e+00
—
—
—
—
cases:3.41%
controls:3.53%
cases:1.55%
controls:1.58%
cases:3.10%
controls:0.19%
—
—
—
—
—
—
—
—
11
114
312
3114
5
51
318
3177
10
6
313
3222
—
—
—
—
Prealbumin [Mass/volume] in Serum or Plasma
14338-8 [3013742]
14338-8 [3013742]
3.0e-01
1.3e+00
—
—
—
2.8e+00
—
cases:2.79%
controls:2.08%
cases:3.41%
controls:0.99%
—
—
—
—
—
—
cases:11.96%
controls:0.79%
—
—
9
67
314
3161
11
32
312
3196
—
—
—
11
25
81
3125
—
cefalexin; oral
J01DB01 [21602870]
J01DB01 [21602870]
1.7e-01
3.7e-01
9.9e-01
—
1.7e+00
1.1e+00
—
cases:31.89%
controls:28.22%
cases:13.00%
controls:9.32%
cases:2.79%
controls:1.05%
—
—
cases:4.59%
controls:0.90%
cases:21.74%
controls:8.13%
—
—
103
911
220
2317
42
301
281
2927
9
34
314
3194
—
10
29
208
3193
20
256
72
2894
—
General anaesthesia
WX402 [2001310806]
WX402 [2001310806]
1.5e-01
1.1e+00
—
1.0e+50
—
2.8e+00
—
cases:2.48%
controls:2.14%
cases:3.41%
controls:1.12%
—
—
cases:3.10%
controls:0.00%
—
—
cases:14.13%
controls:0.98%
—
—
8
69
315
3159
11
36
312
3192
—
10
0
313
3228
—
13
31
79
3119
—
Pain localized to other parts of lower abdomen
R10.3 [45534426]
R10.3 [45534426]
1.2e-02
—
2.8e+00
—
—
—
—
cases:2.48%
controls:2.45%
—
—
cases:2.48%
controls:0.15%
—
—
—
—
—
—
—
—
8
79
315
3149
—
8
5
315
3223
—
—
—
—
Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma
48065-7 [3051714]
48065-7 [3051714]
-1.6e-01
7.6e-01
2.8e+00
—
—
1.5e+00
—
cases:4.64%
controls:5.42%
cases:4.64%
controls:2.23%
cases:3.41%
controls:0.22%
—
—
—
—
cases:8.70%
controls:2.13%
—
—
15
175
308
3053
15
72
308
3156
11
7
312
3221
—
—
8
67
84
3083
—
Methemoglobin/Hemoglobin.total in Arterial blood
2615-3 [3006217]
2615-3 [3006217]
—
8.9e-01
—
—
—
2.8e+00
—
—
—
cases:2.17%
controls:0.90%
—
—
—
—
—
—
cases:7.61%
controls:0.51%
—
—
—
7
29
316
3199
—
—
—
7
16
85
3134
—
Carboxyhemoglobin/Hemoglobin.total in Arterial blood
2030-5 [3028653]
2030-5 [3028653]
—
7.9e-01
—
—
—
2.8e+00
—
—
—
cases:2.17%
controls:0.99%
—
—
—
—
—
—
cases:7.61%
controls:0.51%
—
—
—
7
32
316
3196
—
—
—
7
16
85
3134
—
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]
10839-9 [3021337]
2.3e-01
7.8e-01
2.7e+00
—
1.7e+00
1.0e+00
—
cases:9.60%
controls:7.78%
cases:6.81%
controls:3.25%
cases:6.81%
controls:0.46%
—
—
cases:2.75%
controls:0.50%
cases:9.78%
controls:3.71%
—
—
31
251
292
2977
22
105
301
3123
22
15
301
3213
—
6
16
212
3206
9
117
83
3033
—
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
N02BE01 [21604344]
3.1e-01
3.8e-01
8.2e-01
—
1.1e+00
8.1e-01
—
cases:56.35%
controls:48.57%
cases:38.08%
controls:29.58%
cases:14.24%
controls:6.78%
—
—
cases:18.81%
controls:7.23%
cases:47.83%
controls:29.02%
—
—
182
1568
141
1660
123
955
200
2273
46
219
277
3009
—
41
233
177
2989
44
914
48
2236
—
Chronic ischaemic heart disease, unspecified
I25.9 [45552784]
I25.9 [45552784]
-4.6e-01
4.6e-01
—
—
2.7e+00
—
—
cases:2.17%
controls:3.38%
cases:1.86%
controls:1.18%
—
—
—
—
cases:2.75%
controls:0.19%
—
—
—
—
7
109
316
3119
6
38
317
3190
—
—
6
6
212
3216
—
—
Assessment of need for services (elderly/care support)
SPAT1217 [2001700318]
SPAT1217 [2001700318]
4.4e-01
1.8e-01
—
—
2.7e+00
—
—
cases:4.02%
controls:2.63%
cases:1.55%
controls:1.30%
—
—
—
—
cases:2.29%
controls:0.16%
—
—
—
—
13
85
310
3143
5
42
318
3186
—
—
5
5
213
3217
—
—
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
2276-4 [3001122]
2.0e-01
8.4e-01
1.9e+00
—
7.6e-01
5.7e-01
—
cases:13.93%
controls:11.71%
cases:14.86%
controls:7.00%
cases:4.95%
controls:0.81%
—
—
cases:2.29%
controls:1.09%
cases:11.96%
controls:7.14%
—
—
45
378
278
2850
48
226
275
3002
16
26
307
3202
—
5
35
213
3187
11
225
81
2925
—
Bicarbonate [Moles/volume] in Serum or Plasma
1963-8 [3016293]
1963-8 [3016293]
—
1.0e+00
—
—
—
2.7e+00
—
—
—
cases:2.17%
controls:0.77%
—
—
—
—
—
—
cases:8.70%
controls:0.63%
—
—
—
7
25
316
3203
—
—
—
8
20
84
3130
—
Fractional oxyhemoglobin in Arterial blood
2714-4 [3014007]
2714-4 [3014007]
—
5.8e-01
—
—
—
2.7e+00
—
—
—
cases:1.86%
controls:1.05%
—
—
—
—
—
—
cases:7.61%
controls:0.57%
—
—
—
6
34
317
3194
—
—
—
7
18
85
3132
—
Infiltration anesthesia
WX110 [2001310767]
WX110 [2001310767]
7.6e-02
4.7e-01
1.5e+00
—
—
1.2e+00
—
cases:23.53%
controls:22.18%
cases:12.07%
controls:7.93%
cases:3.72%
controls:0.87%
—
—
—
—
cases:18.48%
controls:6.67%
—
—
76
716
247
2512
39
256
284
2972
12
28
311
3200
—
—
17
210
75
2940
—
Bicarbonate [Moles/volume] standard in Arterial blood
19230-2 [3014218]
19230-2 [3014218]
—
—
—
—
—
2.6e+00
—
—
—
—
—
—
—
—
—
—
—
cases:6.52%
controls:0.51%
—
—
—
—
—
—
—
6
16
86
3134
—
prednisolone; oral, parenteral
H02AB06 [21602734]
H02AB06 [21602734]
4.5e-02
4.5e-01
1.2e+00
—
7.7e-01
1.4e+00
—
cases:15.48%
controls:14.90%
cases:9.91%
controls:6.54%
cases:4.02%
controls:1.21%
—
—
cases:3.67%
controls:1.74%
cases:20.65%
controls:6.25%
—
—
50
481
273
2747
32
211
291
3017
13
39
310
3189
—
8
56
210
3166
19
197
73
2953
—
prednisolone
A07EA01 [21600653]
A07EA01 [21600653]
3.3e-02
4.5e-01
1.2e+00
—
8.9e-01
1.4e+00
—
cases:15.48%
controls:15.06%
cases:9.91%
controls:6.57%
cases:4.02%
controls:1.21%
—
—
cases:4.13%
controls:1.74%
cases:20.65%
controls:6.29%
—
—
50
486
273
2742
32
212
291
3016
13
39
310
3189
—
9
56
209
3166
19
198
73
2952
—
pH of Specimen
17433-4 [3019225]
17433-4 [3019225]
7.0e-01
6.7e-01
2.6e+00
—
—
—
—
cases:6.19%
controls:3.16%
cases:3.10%
controls:1.61%
cases:2.79%
controls:0.22%
—
—
—
—
—
—
—
—
20
102
303
3126
10
52
313
3176
9
7
314
3221
—
—
—
—
Cathetrisation of artery
TPH07 [2001309747]
TPH07 [2001309747]
4.9e-01
—
—
1.0e+50
—
2.6e+00
—
cases:3.10%
controls:1.92%
—
—
—
—
cases:1.55%
controls:0.00%
—
—
cases:6.52%
controls:0.54%
—
—
10
62
313
3166
—
—
5
0
318
3228
—
6
17
86
3133
—
Cancer Ag 19-9 [Units/volume] in Serum or Plasma by Immunoassay
83084-4 [42529201]
83084-4 [42529201]
2.5e+00
—
1.0e+50
—
1.0e+50
—
—
cases:1.86%
controls:0.15%
—
—
cases:9.29%
controls:0.00%
—
—
cases:13.76%
controls:0.00%
—
—
—
—
6
5
317
3223
—
30
0
293
3228
—
30
0
188
3222
—
—
Constipation
D12 [2002000311]
D12 [2002000311]
—
2.5e+00
—
—
—
-1.0e+50
—
—
—
cases:2.17%
controls:0.19%
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
7
6
316
3222
—
—
—
0
11
92
3139
—
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD)/1.73 sq M
77147-7 [46236952]
77147-7 [46236952]
-8.5e-02
—
2.5e+00
—
—
—
—
cases:2.17%
controls:2.35%
—
—
cases:2.17%
controls:0.19%
—
—
—
—
—
—
—
—
7
76
316
3152
—
7
6
316
3222
—
—
—
—
Mycobacterium tuberculosis DNA [Presence] in Specimen by NAA with probe detection
13956-8 [3014162]
13956-8 [3014162]
7.0e-01
2.5e+00
—
—
—
-1.0e+50
—
cases:1.55%
controls:0.77%
cases:2.17%
controls:0.19%
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
5
25
318
3203
7
6
316
3222
—
—
—
0
11
92
3139
—
Neoplasm of uncertain or unknown behaviour: Other digestive organs
D37.7 [45552349]
D37.7 [45552349]
2.5e+00
—
—
1.0e+50
1.0e+50
—
—
cases:2.17%
controls:0.19%
—
—
—
—
cases:2.17%
controls:0.00%
cases:2.75%
controls:0.00%
—
—
—
—
7
6
316
3222
—
—
7
0
316
3228
6
0
212
3222
—
—
Metamyelocytes/Leukocytes in Blood
28541-1 [3002179]
28541-1 [3002179]
8.1e-01
—
2.5e+00
—
—
—
—
cases:2.48%
controls:1.12%
—
—
cases:2.48%
controls:0.22%
—
—
—
—
—
—
—
—
8
36
315
3192
—
8
7
315
3221
—
—
—
—
Hemoglobin [Mass/volume] in Arterial blood
30313-1 [3002173]
30313-1 [3002173]
—
7.5e-01
—
1.0e+50
—
2.4e+00
—
—
—
cases:2.79%
controls:1.33%
—
—
cases:1.86%
controls:0.00%
—
—
cases:9.78%
controls:0.95%
—
—
—
9
43
314
3185
—
6
0
317
3228
—
9
30
83
3120
—
Hematology
82 [38004501]
82 [38004501]
1.1e+00
1.5e+00
—
—
—
2.4e+00
—
cases:2.48%
controls:0.87%
cases:2.48%
controls:0.59%
—
—
—
—
—
—
cases:5.43%
controls:0.51%
—
—
8
28
315
3200
8
19
315
3209
—
—
—
5
16
87
3134
—
Oxygen saturation in Arterial blood
2708-6 [3016502]
2708-6 [3016502]
-6.6e-01
5.6e-01
—
1.0e+50
—
2.4e+00
—
cases:1.55%
controls:2.94%
cases:2.79%
controls:1.61%
—
—
cases:1.86%
controls:0.00%
—
—
cases:10.87%
controls:1.08%
—
—
5
95
318
3133
9
52
314
3176
—
6
0
317
3228
—
10
34
82
3116
—
Telephone prescription or other care instructions
WZB00 [2001310884]
WZB00 [2001310884]
2.1e-01
7.5e-01
—
—
—
2.4e+00
—
cases:5.88%
controls:4.80%
cases:3.10%
controls:1.49%
—
—
—
—
—
—
cases:8.70%
controls:0.86%
—
—
19
155
304
3073
10
48
313
3180
—
—
—
8
27
84
3123
—
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
M01AE01 [21603967]
3.5e-02
7.1e-02
4.8e-01
—
1.2e+00
1.1e+00
—
cases:29.72%
controls:29.00%
cases:12.07%
controls:11.34%
cases:2.48%
controls:1.55%
—
—
cases:5.50%
controls:1.68%
cases:26.09%
controls:10.19%
—
—
96
936
227
2292
39
366
284
2862
8
50
315
3178
—
12
54
206
3168
24
321
68
2829
—
ibuprofen
R02AX02 [1588667]
R02AX02 [1588667]
3.5e-02
7.1e-02
4.8e-01
—
1.2e+00
1.1e+00
—
cases:29.72%
controls:29.00%
cases:12.07%
controls:11.34%
cases:2.48%
controls:1.55%
—
—
cases:5.50%
controls:1.68%
cases:26.09%
controls:10.19%
—
—
96
936
227
2292
39
366
284
2862
8
50
315
3178
—
12
54
206
3168
24
321
68
2829
—
Respiratory and circulatory monitoring
WX700 [2001310817]
WX700 [2001310817]
3.2e-01
3.6e-01
—
1.0e+50
—
2.3e+00
—
cases:4.33%
controls:3.19%
cases:1.55%
controls:1.08%
—
—
cases:1.86%
controls:0.00%
—
—
cases:7.61%
controls:0.79%
—
—
14
103
309
3125
5
35
318
3193
—
6
0
317
3228
—
7
25
85
3125
—
Insertion of central venous catheter through external or internal jugular vein
TPH15 [2001309600]
TPH15 [2001309600]
—
2.3e+00
1.0e+50
—
—
—
—
—
—
cases:1.86%
controls:0.19%
cases:1.55%
controls:0.00%
—
—
—
—
—
—
—
—
—
6
6
317
3222
5
0
318
3228
—
—
—
—
Infectious Disease
44 [38004484]
44 [38004484]
2.4e-01
—
2.3e+00
—
-1.0e+50
—
—
cases:2.79%
controls:2.20%
—
—
cases:1.86%
controls:0.19%
—
—
cases:0.00%
controls:0.16%
—
—
—
—
9
71
314
3157
—
6
6
317
3222
—
0
5
218
3217
—
—
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
GD1UA [2001303652]
-8.8e-02
1.2e+00
—
—
—
2.3e+00
—
cases:2.79%
controls:3.04%
cases:3.10%
controls:0.99%
—
—
—
—
—
—
cases:8.70%
controls:0.95%
—
—
9
98
314
3130
10
32
313
3196
—
—
—
8
30
84
3120
—
Cortisol [Moles/volume] in Serum or Plasma
14675-3 [3036481]
14675-3 [3036481]
-2.1e-01
5.2e-01
—
—
—
2.2e+00
—
cases:1.86%
controls:2.29%
cases:1.55%
controls:0.93%
—
—
—
—
—
—
cases:8.70%
controls:1.02%
—
—
6
74
317
3154
5
30
318
3198
—
—
—
8
32
84
3118
—
Pain in limb
M79.6 [45587063]
M79.6 [45587063]
7.0e-02
2.6e-02
2.2e+00
—
-1.0e+50
—
—
cases:8.98%
controls:8.43%
cases:3.72%
controls:3.62%
cases:2.79%
controls:0.31%
—
—
cases:0.00%
controls:0.37%
—
—
—
—
29
272
294
2956
12
117
311
3111
9
10
314
3218
—
0
12
218
3210
—
—
Myelocytes/Leukocytes in Blood
26498-6 [3017181]
26498-6 [3017181]
5.2e-01
—
2.2e+00
—
—
—
—
cases:2.48%
controls:1.49%
—
—
cases:2.48%
controls:0.28%
—
—
—
—
—
—
—
—
8
48
315
3180
—
8
9
315
3219
—
—
—
—
Promyelocytes/Leukocytes in Blood
26524-9 [3021440]
26524-9 [3021440]
6.1e-01
—
2.2e+00
—
—
—
—
cases:2.48%
controls:1.36%
—
—
cases:2.48%
controls:0.28%
—
—
—
—
—
—
—
—
8
44
315
3184
—
8
9
315
3219
—
—
—
—
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
40987-0 [3043924]
-4.5e-02
8.4e-01
2.2e+00
—
1.9e+00
1.4e+00
—
cases:2.79%
controls:2.91%
cases:3.72%
controls:1.64%
cases:2.17%
controls:0.25%
—
—
cases:2.29%
controls:0.34%
cases:8.70%
controls:2.29%
—
—
9
94
314
3134
12
53
311
3175
7
8
316
3220
—
5
11
213
3211
8
72
84
3078
—
Mycobacterium sp identified in Specimen by Organism specific culture
543-9 [3005702]
543-9 [3005702]
—
2.2e+00
—
—
—
-1.0e+50
—
—
—
cases:2.17%
controls:0.25%
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
—
7
8
316
3220
—
—
—
0
5
92
3145
—
Pleural effusion, not elsewhere classified
J90 [45605897]
J90 [45605897]
—
2.2e+00
—
—
—
—
—
—
—
cases:1.86%
controls:0.22%
—
—
—
—
—
—
—
—
—
—
—
6
7
317
3221
—
—
—
—
—
Flexible bronchoscopy
UGC12 [2001303610]
UGC12 [2001303610]
7.0e-01
2.2e+00
—
—
—
—
—
cases:1.86%
controls:0.93%
cases:1.86%
controls:0.22%
—
—
—
—
—
—
—
—
—
—
6
30
317
3198
6
7
317
3221
—
—
—
—
—
Endocrinology
46 [38004485]
46 [38004485]
3.4e-01
6.7e-01
—
—
—
2.2e+00
—
cases:4.33%
controls:3.13%
cases:3.10%
controls:1.61%
—
—
—
—
—
—
cases:10.87%
controls:1.40%
—
—
14
101
309
3127
10
52
313
3176
—
—
—
10
44
82
3106
—
Ultrasound examination of lower leg veins
PH2AE [2001309451]
PH2AE [2001309451]
1.3e-01
—
—
—
—
2.1e+00
—
cases:1.86%
controls:1.64%
—
—
—
—
—
—
—
—
cases:5.43%
controls:0.67%
—
—
6
53
317
3175
—
—
—
—
5
21
87
3129
—
Blasts/Leukocytes in Blood
26446-5 [3025159]
26446-5 [3025159]
4.6e-01
3.3e-01
2.1e+00
—
—
—
—
cases:1.86%
controls:1.18%
cases:1.55%
controls:1.12%
cases:2.48%
controls:0.31%
—
—
—
—
—
—
—
—
6
38
317
3190
5
36
318
3192
8
10
315
3218
—
—
—
—
Excision of other lesion extending through all layers of skin in head or neck
QAE10 [2001309784]
QAE10 [2001309784]
2.1e+00
—
—
—
—
—
—
cases:2.17%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
7
9
316
3219
—
—
—
—
—
—
Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]
40982-1 [3038288]
1.5e-01
8.7e-01
2.1e+00
—
1.9e+00
1.4e+00
—
cases:3.41%
controls:2.94%
cases:4.02%
controls:1.73%
cases:2.17%
controls:0.28%
—
—
cases:2.29%
controls:0.34%
cases:8.70%
controls:2.29%
—
—
11
95
312
3133
13
56
310
3172
7
9
316
3219
—
5
11
213
3211
8
72
84
3078
—
ECG with 12 standard connections
XF400 [2001303368]
XF400 [2001303368]
-7.8e-02
1.2e+00
—
—
—
2.1e+00
—
cases:2.79%
controls:3.00%
cases:2.79%
controls:0.84%
—
—
—
—
—
—
cases:5.43%
controls:0.73%
—
—
9
97
314
3131
9
27
314
3201
—
—
—
5
23
87
3127
—
Calculus of gallbladder without cholecystitis
K80.2 [45552951]
K80.2 [45552951]
8.4e-01
2.0e+00
—
—
—
-1.0e+50
—
cases:2.48%
controls:1.08%
cases:1.86%
controls:0.25%
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
8
35
315
3193
6
8
317
3220
—
—
—
0
12
92
3138
—
Other specified chronic obstructive pulmonary disease
J44.8 [45586673]
J44.8 [45586673]
6.3e-01
5.6e-01
1.5e+00
—
2.0e+00
—
—
cases:5.57%
controls:3.04%
cases:2.79%
controls:1.61%
cases:1.86%
controls:0.43%
—
—
cases:2.75%
controls:0.37%
—
—
—
—
18
98
305
3130
9
52
314
3176
6
14
317
3214
—
6
12
212
3210
—
—
Sedation and analgesia
WX002 [2001310758]
WX002 [2001310758]
2.7e-01
1.2e+00
-1.0e+50
—
—
2.0e+00
—
cases:5.57%
controls:4.31%
cases:3.10%
controls:0.93%
cases:0.00%
controls:0.19%
—
—
—
—
cases:6.52%
controls:0.95%
—
—
18
139
305
3089
10
30
313
3198
0
6
323
3222
—
—
6
30
86
3120
—
Prostate Specific Ag Free [Mass/volume] in Serum or Plasma
10886-0 [3005013]
10886-0 [3005013]
-3.9e-02
2.9e-01
1.6e+00
—
2.0e+00
—
—
cases:8.67%
controls:8.98%
cases:5.57%
controls:4.21%
cases:2.48%
controls:0.53%
—
—
cases:3.21%
controls:0.47%
—
—
—
—
28
290
295
2938
18
136
305
3092
8
17
315
3211
—
7
15
211
3207
—
—
Fall on same level from slipping, tripping and stumbling
W01 [45756243]
W01 [45756243]
-8.6e-02
4.6e-01
1.9e+00
—
1.8e+00
9.3e-01
—
cases:7.12%
controls:7.71%
cases:4.95%
controls:3.19%
cases:2.48%
controls:0.37%
—
—
cases:2.29%
controls:0.37%
cases:7.61%
controls:3.14%
—
—
23
249
300
2979
16
103
307
3125
8
12
315
3216
—
5
12
213
3210
7
99
85
3051
—
Pain localized to upper abdomen
R10.1 [45568111]
R10.1 [45568111]
-6.3e-01
1.9e+00
—
—
—
—
—
cases:1.55%
controls:2.88%
cases:4.33%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
5
93
318
3135
14
22
309
3206
—
—
—
—
—
Extensive body CT
JN4BD [2001310899]
JN4BD [2001310899]
1.9e+00
—
1.0e+50
—
1.0e+50
—
—
cases:4.02%
controls:0.65%
—
—
cases:5.26%
controls:0.00%
—
—
cases:4.59%
controls:0.00%
—
—
—
—
13
21
310
3207
—
17
0
306
3228
—
10
0
208
3222
—
—
Abnormal findings on diagnostic imaging of lung
R91 [45548995]
R91 [45548995]
6.8e-01
1.9e+00
—
—
—
—
—
cases:2.79%
controls:1.43%
cases:4.02%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
9
46
314
3182
13
21
310
3207
—
—
—
—
—
Extended examination of mouth
SAA03 [2001310276]
SAA03 [2001310276]
-2.8e-01
-1.7e-02
—
—
—
1.9e+00
—
cases:6.50%
controls:8.40%
cases:1.86%
controls:1.89%
—
—
—
—
—
—
cases:6.52%
controls:1.08%
—
—
21
271
302
2957
6
61
317
3167
—
—
—
6
34
86
3116
—
macrogol; oral
A06AD15 [21600575]
A06AD15 [21600575]
1.2e-01
5.9e-01
—
—
1.6e+00
1.8e+00
—
cases:3.10%
controls:2.76%
cases:3.10%
controls:1.73%
—
—
—
—
cases:3.21%
controls:0.65%
cases:9.78%
controls:1.84%
—
—
10
89
313
3139
10
56
313
3172
—
—
7
21
211
3201
9
58
83
3092
—
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
72160-5 [43054903]
-9.5e-02
3.1e-01
1.7e+00
—
1.2e+00
5.5e-01
—
cases:14.55%
controls:15.77%
cases:10.84%
controls:8.18%
cases:4.02%
controls:0.74%
—
—
cases:2.75%
controls:0.81%
cases:14.13%
controls:8.67%
—
—
47
509
276
2719
35
264
288
2964
13
24
310
3204
—
6
26
212
3196
13
273
79
2877
—
Chronic apical periodontitis
K04.5 [45586691]
K04.5 [45586691]
4.7e-01
9.2e-01
—
—
—
1.7e+00
—
cases:8.98%
controls:5.79%
cases:3.72%
controls:1.52%
—
—
—
—
—
—
cases:7.61%
controls:1.46%
—
—
29
187
294
3041
12
49
311
3179
—
—
—
7
46
85
3104
—
Anaemia, unspecified
D64.9 [45600610]
D64.9 [45600610]
4.2e-01
1.7e+00
—
—
—
—
—
cases:3.41%
controls:2.26%
cases:4.33%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
11
73
312
3155
14
27
309
3201
—
—
—
—
—
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
14920-3 [3008486]
-1.9e-01
2.9e-02
1.6e+00
—
—
5.9e-01
—
cases:26.93%
controls:30.76%
cases:16.41%
controls:16.02%
cases:6.81%
controls:1.43%
—
—
—
—
cases:23.91%
controls:14.83%
—
—
87
993
236
2235
53
517
270
2711
22
46
301
3182
—
—
22
467
70
2683
—
Protein [Presence] in Urine by Test strip
20454-5 [3014051]
20454-5 [3014051]
8.2e-02
7.1e-01
1.6e+00
—
1.7e+00
6.5e-01
—
cases:7.12%
controls:6.60%
cases:7.12%
controls:3.62%
cases:3.41%
controls:0.71%
—
—
cases:2.75%
controls:0.50%
cases:8.70%
controls:4.73%
—
—
23
213
300
3015
23
117
300
3111
11
23
312
3205
—
6
16
212
3206
8
149
84
3001
—
amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]
J01CR02 [21602863]
3.0e-02
6.7e-01
—
—
—
1.6e+00
—
cases:8.98%
controls:8.74%
cases:4.02%
controls:2.11%
—
—
—
—
—
—
cases:8.70%
controls:1.90%
—
—
29
282
294
2946
13
68
310
3160
—
—
—
8
60
84
3090
—
X-ray examination of the lungs in one projection
GD1PA [2001303645]
GD1PA [2001303645]
7.5e-01
1.6e+00
—
—
—
—
—
cases:3.10%
controls:1.49%
cases:2.79%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
10
48
313
3180
9
19
314
3209
—
—
—
—
—
SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
94500-6 [706163]
94500-6 [706163]
4.8e-02
2.8e-01
1.6e+00
—
1.3e+00
2.1e-01
—
cases:9.29%
controls:8.89%
cases:8.67%
controls:6.69%
cases:4.02%
controls:0.87%
—
—
cases:3.67%
controls:0.99%
cases:9.78%
controls:8.10%
—
—
30
287
293
2941
28
216
295
3012
13
28
310
3200
—
8
32
210
3190
9
255
83
2895
—
Body height measure
50373000 [4177340]
50373000 [4177340]
-3.1e-01
1.5e-02
1.5e+00
—
—
1.0e+50
—
cases:17.03%
controls:21.81%
cases:6.19%
controls:6.10%
cases:3.41%
controls:0.77%
—
—
—
—
cases:16.30%
controls:0.00%
—
—
55
704
268
2524
20
197
303
3031
11
25
312
3203
—
—
15
0
77
3150
—
Body mass index
60621009 [4245997]
60621009 [4245997]
-3.0e-01
2.1e-02
1.5e+00
—
—
1.0e+50
—
cases:17.03%
controls:21.69%
cases:6.19%
controls:6.07%
cases:3.41%
controls:0.77%
—
—
—
—
cases:16.30%
controls:0.00%
—
—
55
700
268
2528
20
196
303
3032
11
25
312
3203
—
—
15
0
77
3150
—
oxazepam; oral
N05BA04 [21604569]
N05BA04 [21604569]
2.1e-02
1.4e-01
6.6e-01
—
1.5e+00
6.9e-01
—
cases:6.19%
controls:6.07%
cases:4.33%
controls:3.78%
cases:2.48%
controls:1.30%
—
—
cases:4.59%
controls:1.06%
cases:7.61%
controls:3.97%
—
—
20
196
303
3032
14
122
309
3106
8
42
315
3186
—
10
34
208
3188
7
125
85
3025
—
Atherosclerotic heart disease
I25.1 [45596196]
I25.1 [45596196]
-2.5e-01
-3.2e-01
1.1e+00
—
1.4e+00
-4.7e-02
—
cases:8.36%
controls:10.44%
cases:4.33%
controls:5.86%
cases:4.02%
controls:1.43%
—
—
cases:4.59%
controls:1.12%
cases:5.43%
controls:5.68%
—
—
27
337
296
2891
14
189
309
3039
13
46
310
3182
—
10
36
208
3186
5
179
87
2971
—
Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma
14685-2 [3009035]
14685-2 [3009035]
-1.9e-01
4.1e-01
—
—
—
1.4e+00
—
cases:8.98%
controls:10.63%
cases:4.95%
controls:3.35%
—
—
—
—
—
—
cases:10.87%
controls:2.83%
—
—
29
343
294
2885
16
108
307
3120
—
—
—
10
89
82
3061
—
zopiclone; oral
N05CF01 [21604654]
N05CF01 [21604654]
2.6e-01
2.3e-01
4.1e-01
—
1.4e+00
5.9e-01
—
cases:13.62%
controls:10.84%
cases:8.05%
controls:6.51%
cases:2.79%
controls:1.86%
—
—
cases:7.80%
controls:1.99%
cases:10.87%
controls:6.32%
—
—
44
350
279
2878
26
210
297
3018
9
60
314
3168
—
17
64
201
3158
10
199
82
2951
—
Limited function/disability NOS
A28 [2002000162]
A28 [2002000162]
1.8e-01
6.8e-01
1.0e+00
—
1.4e+00
5.0e-01
—
cases:6.81%
controls:5.73%
cases:6.81%
controls:3.56%
cases:4.02%
controls:1.52%
—
—
cases:5.50%
controls:1.46%
cases:6.52%
controls:4.06%
—
—
22
185
301
3043
22
115
301
3113
13
49
310
3179
—
12
47
206
3175
6
128
86
3022
—
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
3016-3 [3009201]
-1.3e-01
3.1e-02
1.3e+00
—
-2.2e-01
1.4e-02
—
cases:39.63%
controls:42.72%
cases:24.77%
controls:24.19%
cases:8.98%
controls:2.51%
—
—
cases:2.29%
controls:2.86%
cases:23.91%
controls:23.65%
—
—
128
1379
195
1849
80
781
243
2447
29
81
294
3147
—
5
92
213
3130
22
745
70
2405
—
Colonoscopy Study observation
28023-0 [3022145]
28023-0 [3022145]
4.0e-01
1.3e+00
—
—
—
1.7e+00
—
cases:3.72%
controls:2.51%
cases:3.41%
controls:0.93%
—
—
—
—
—
—
cases:5.43%
controls:1.05%
—
—
12
81
311
3147
11
30
312
3198
—
—
—
5
33
87
3117
—
Sampling
SPAT1263 [2001700364]
SPAT1263 [2001700364]
6.2e-02
2.5e-01
1.2e+00
—
—
1.6e-01
—
cases:17.03%
controls:16.17%
cases:8.36%
controls:6.63%
cases:3.72%
controls:1.12%
—
—
—
—
cases:6.52%
controls:5.59%
—
—
55
522
268
2706
27
214
296
3014
12
36
311
3192
—
—
6
176
86
2974
—
Telehealth
OMOP5556618 [722455]
OMOP5556618 [722455]
1.5e-01
2.8e-01
1.1e+00
—
7.4e-01
4.9e-01
—
cases:41.80%
controls:38.23%
cases:17.34%
controls:13.66%
cases:6.19%
controls:2.23%
—
—
cases:5.05%
controls:2.48%
cases:15.22%
controls:9.90%
—
—
135
1234
188
1994
56
441
267
2787
20
72
303
3156
—
11
80
207
3142
14
312
78
2838
—
Plastic And Reconstructive Surgery
24 [38004467]
24 [38004467]
1.1e+00
1.2e+00
—
—
—
-1.0e+50
—
cases:5.57%
controls:2.01%
cases:2.48%
controls:0.77%
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
18
65
305
3163
8
25
315
3203
—
—
—
0
24
92
3126
—
folic acid; oral, parenteral
B03BB01 [21601129]
B03BB01 [21601129]
1.7e-01
1.0e+00
—
—
-1.0e+50
—
—
cases:2.17%
controls:1.83%
cases:4.95%
controls:1.83%
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
7
59
316
3169
16
59
307
3169
—
—
0
27
218
3195
—
—
folic acid
V04CX02 [715877]
V04CX02 [715877]
1.7e-01
1.0e+00
—
—
-1.0e+50
—
—
cases:2.17%
controls:1.83%
cases:4.95%
controls:1.83%
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
7
59
316
3169
16
59
307
3169
—
—
0
27
218
3195
—
—
Hemoglobin A1c/Hemoglobin.total in Blood
4548-4 [3004410]
4548-4 [3004410]
-6.5e-02
-7.4e-02
8.8e-01
—
1.1e-02
-7.6e-01
—
cases:43.34%
controls:44.95%
cases:28.79%
controls:30.33%
cases:9.29%
controls:4.06%
—
—
cases:3.67%
controls:3.63%
cases:17.39%
controls:31.05%
—
—
140
1451
183
1777
93
979
230
2249
30
131
293
3097
—
8
117
210
3105
16
978
76
2172
—
buprenorphine; parenteral, sublingual, transdermal
N02AE01 [21604287]
N02AE01 [21604287]
3.3e-01
8.8e-01
8.6e-01
—
—
—
—
cases:5.57%
controls:4.09%
cases:6.19%
controls:2.66%
cases:2.17%
controls:0.93%
—
—
—
—
—
—
—
—
18
132
305
3096
20
86
303
3142
7
30
316
3198
—
—
—
—
Sciatica
M54.3 [45586994]
M54.3 [45586994]
1.4e+00
—
—
—
—
—
—
cases:1.55%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
—
5
12
318
3216
—
—
—
—
—
—
Protein.monoclonal band 4 [Mass/volume] in Serum or Plasma by Electrophoresis
50797-0 [3029379]
50797-0 [3029379]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
0
9
92
3141
—
Chronic disorders of vitamin D metabolism
123 [2001600122]
123 [2001600122]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.19%
cases:0.00%
controls:0.15%
—
—
—
—
—
—
—
—
—
—
0
6
323
3222
0
5
323
3223
—
—
—
—
—
Plastic repair of septum of nose
DJD20 [2001301709]
DJD20 [2001301709]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.22%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
323
3221
—
—
—
—
—
—
celiprolol; oral
C07AB08 [21601690]
C07AB08 [21601690]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
0
18
323
3210
—
—
—
0
18
92
3132
—
Extensive ear examination
SPAT1351 [2001700452]
SPAT1351 [2001700452]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
323
3222
—
—
—
—
—
—
Screening procedure
SPAT1324 [2001700425]
SPAT1324 [2001700425]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
0
15
323
3213
—
—
—
0
15
92
3135
—
Exposure to other specified factors
X58 [45756411]
X58 [45756411]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
—
0
14
92
3136
—
Primary arthrosis of other joints
M19.0 [45601353]
M19.0 [45601353]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
0
26
92
3124
—
Exudative senile macular degeneration
362.52 [44828900]
362.52 [44828900]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.19%
—
—
—
—
—
—
—
0
6
92
3144
—
Day surgery
ZXD20 [2001311388]
ZXD20 [2001311388]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.15%
—
—
—
—
—
—
—
—
—
—
—
0
5
323
3223
—
—
—
—
—
Borrelia burgdorferi IgG Ab [Units/volume] in Cerebral spinal fluid
22126-7 [3010380]
22126-7 [3010380]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
323
3220
—
—
—
—
—
—
Examination and observation for other reasons
Z04 [45609904]
Z04 [45609904]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
323
3219
—
—
—
—
—
—
dydrogesterone; oral
G03DB01 [21602544]
G03DB01 [21602544]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
323
3222
—
—
—
—
—
—
Other orthopedic bandage, unspecified region
TNX39 [2001308566]
TNX39 [2001308566]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.15%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
323
3223
—
—
—
—
—
—
Social problem NOS
Z29 [2002001483]
Z29 [2002001483]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.19%
—
—
—
—
—
—
—
0
6
92
3144
—
Hand Surgery
40 [38004480]
40 [38004480]
—
-1.0e+50
—
—
-1.0e+50
-1.0e+50
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
cases:0.00%
controls:0.16%
cases:0.00%
controls:0.98%
—
—
—
0
28
323
3200
—
—
0
5
218
3217
0
31
92
3119
—
Urinary tract infection, site not specified
N39.0 [45548665]
N39.0 [45548665]
2.5e-01
5.9e-01
—
—
—
-1.0e+50
—
cases:4.64%
controls:3.66%
cases:2.17%
controls:1.21%
—
—
—
—
—
—
cases:0.00%
controls:1.71%
—
—
15
118
308
3110
7
39
316
3189
—
—
—
0
54
92
3096
—
Cardiac arrhythmia NOS
K80 [2002000607]
K80 [2002000607]
1.5e-01
—
—
—
—
-1.0e+50
—
cases:1.55%
controls:1.33%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
5
43
318
3185
—
—
—
—
0
19
92
3131
—
Extensive CT of head and brain
AA1BD [2001300110]
AA1BD [2001300110]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.22%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
323
3221
—
—
—
—
—
—
Fracture of nasal bones, closed
S02.20 [45755755]
S02.20 [45755755]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.15%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
323
3223
—
—
—
—
—
—
Angina pectoris, unspecified
I20.91 [2000502403]
I20.91 [2000502403]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
323
3222
—
—
—
—
—
—
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
R29.8 [45587505]
R29.8 [45587505]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.28%
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
0
9
323
3219
—
—
—
0
8
92
3142
—
chlorhexidine
S02AA09 [21605155]
S02AA09 [21605155]
2.9e-01
7.4e-01
—
—
—
—
—
cases:2.79%
controls:2.11%
cases:1.55%
controls:0.74%
—
—
—
—
—
—
—
—
—
—
9
68
314
3160
5
24
318
3204
—
—
—
—
—
azelaic acid; ointment
D10AX03 [21602314]
D10AX03 [21602314]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.37%
cases:0.00%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
0
12
323
3216
0
6
323
3222
—
—
—
—
—
Other spondylosis, multiple sites in spine
M47.80 [42617655]
M47.80 [42617655]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
323
3215
—
—
—
—
—
—
long-acting sulfonamides - combinations
J01ED20 [21602959]
J01ED20 [21602959]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
0
5
92
3145
—
lidocaine, combinations
N01BB52 [21604241]
N01BB52 [21604241]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
0
9
92
3141
—
indapamide; oral
C03BA11 [21601499]
C03BA11 [21601499]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.46%
cases:0.00%
controls:0.15%
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
0
15
323
3213
0
5
323
3223
—
—
—
0
5
92
3145
—
Palpitations/awareness of heart
K04 [2002000547]
K04 [2002000547]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
0
8
92
3142
—
LabWAS
↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
195
141
33.19
233.47
3.6
1.4
199.08
2.89
ug/l
2.63
175
112
112
49
34.37
161.74
3.3
1.9
5161.11
17.03
u/ml
2.00
101
38
44
20
25.28
60.62
1.3
1.8
118.43
187.77
u/ml
0.14
44
20
246
1259
4.95
36.82
12.6
3.7
15.65
12.28
umol/l
1.25
239
1185
38
10
42.74
31.00
4.1
1.6
7.97
5.18
nmol/l
—
38
10
171
794
3.44
26.66
3.0
2.3
47.46
63.63
u/l
1.87
161
732
209
1149
3.30
23.66
7.9
3.8
30.51
34.91
g/l
15.74
201
1073
222
1284
3.31
22.66
15.2
5.4
5.39
4.42
e9/l
3.49
194
1099
218
1350
2.87
17.80
11.9
17.3
1.28
1.36
inr
1.11
182
1132
21
6
37.23
16.87
5.2
1.0
141.71
92.83
nmol/l
—
21
6
64
209
3.57
16.60
2.0
1.9
0.18
0.20
g/l
1.57
58
187
23
32
7.65
15.86
1.3
1.5
3610.38
2105.41
e6/l
0.25
13
22
71
257
3.25
15.59
3.3
2.0
17.67
7.59
umol/l
1.59
71
225
14
0
+∞
14.69
5.6
0.0
62.22
—
u/ml
—
14
0
174
1047
2.43
13.73
3.0
2.4
—
—
estimate
—
0
0
113
565
2.53
13.33
2.5
2.0
—
—
—
0
0
16
5
33.50
12.68
1.4
1.0
2205.80
395.40
e6/l
—
10
5
255
1868
2.71
12.49
15.6
5.4
139.24
79.02
u/l
8.80
244
1728
37
992
0.29
12.27
1.7
2.0
1.32
1.28
mmol/l
0.06
29
806
22
24
9.74
11.18
1.3
1.5
45757.27
2340.31
e6/l
0.86
11
13
198
1356
2.18
10.36
6.7
6.2
1.20
1.21
mmol/l
0.54
168
1160
181
1212
2.11
9.86
6.2
5.5
1.20
1.21
mmol/l
1.38
174
1086
21
50
4.42
8.31
1.5
1.5
—
—
—
0
0
21
53
4.16
7.73
1.4
1.3
—
—
—
0
0
210
1575
1.94
7.39
5.1
4.4
6.96
6.90
mmol/l
0.16
199
1499
75
421
2.01
6.11
2.7
1.7
29.47
29.42
s
0.03
75
404
80
474
1.91
5.54
2.2
2.5
10.98
12.44
umol/l
0.97
70
440
5
0
+∞
5.22
2.0
0.0
48.76
—
pmol/l
—
5
0
211
1678
1.73
5.19
4.9
4.9
1240.29
2056.44
e6/l
—
7
34
74
436
1.90
5.18
2.1
2.5
2.14
2.25
g/l
0.95
67
403
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
25
94
2.80
5.03
3.1
2.4
0.40
0.41
iu/ml
0.07
18
55
83
514
1.82
4.96
1.9
1.8
—
—
—
0
0
203
2398
0.59
4.87
4.1
6.4
2.63
2.53
mmol/l
0.74
172
2187
9
10
9.21
4.81
1.4
1.5
—
—
—
0
0
112
763
1.71
4.80
4.5
2.6
48.86
35.92
u/l
1.33
107
720
198
2339
0.60
4.50
3.8
5.5
4.51
4.42
mmol/l
0.50
171
2145
16
51
3.25
4.26
3.6
2.2
97.00
87.86
%
0.73
16
51
67
406
1.82
4.25
2.3
2.4
20.77
22.41
%
0.28
59
377
198
2317
0.62
3.98
3.7
5.4
1.40
1.45
mmol/l
0.74
171
2099
199
2321
0.63
3.87
5.9
7.5
41.18
40.77
mmol/mol
0.25
176
2148
105
739
1.62
3.83
3.4
3.1
2.59
0.53
e6/l
0.89
78
548
206
2376
0.63
3.68
4.0
5.6
6.17
6.14
mmol/l
0.11
171
2134
11
26
4.34
3.53
1.4
1.2
—
—
—
0
0
71
1019
0.61
3.33
3.8
4.1
25.08
7.05
mg/mmol
0.69
45
661
190
2209
0.66
3.25
3.4
4.7
1.35
1.26
mmol/l
1.07
162
1976
11
29
3.88
3.21
1.3
1.4
—
—
—
0
0
52
321
1.74
3.08
3.3
3.0
1.93
2.07
mmol/l
0.08
45
277
29
149
2.04
3.00
1.4
1.5
—
—
—
0
0
123
943
1.49
2.93
3.7
3.2
—
—
—
0
0
21
97
2.24
2.83
2.8
3.5
—
—
—
0
0
61
416
1.57
2.46
2.9
3.1
2.45
2.38
e6/l
0.03
25
194
100
759
1.46
2.44
2.4
2.3
3.00
2.97
mg/l
0.05
84
645
55
377
1.55
2.17
1.8
1.8
—
—
—
0
0
53
365
1.54
2.05
5.2
6.1
11.94
11.18
kpa
0.55
53
349
53
365
1.54
2.05
5.2
6.1
5.05
5.11
kpa
0.23
53
349
52
358
1.54
2.02
4.8
6.2
1.56
1.15
mmol/l
0.34
45
291
33
204
1.69
1.98
1.6
1.5
—
—
—
0
0
23
387
0.56
1.93
1.1
1.3
1.62
10.57
u/ml
—
6
129
13
58
2.29
1.93
1.5
1.3
—
—
—
0
0
13
58
2.29
1.93
1.5
1.3
—
—
—
0
0
27
160
1.75
1.88
2.7
4.3
2.48
2.28
mmol/l
0.09
20
114
30
189
1.65
1.69
2.7
4.3
5.11
5.14
kpa
0.06
30
181
83
648
1.38
1.68
3.3
2.5
342.21
363.99
umol/l
0.99
68
558
14
69
2.07
1.67
1.2
1.2
141.00
330.87
ug/g
—
6
43
27
418
0.61
1.66
1.1
1.3
35.02
37.35
iu/ml
—
5
129
76
587
1.38
1.64
1.9
1.8
1101.64
1200.40
nmol/l
0.29
60
451
27
167
1.67
1.64
8.3
8.1
15.79
15.63
%
0.10
27
161
19
106
1.84
1.62
2.3
1.7
—
—
—
0
0
5
14
3.61
1.62
1.2
1.0
—
—
—
0
0
32
209
1.59
1.58
4.3
5.3
24.97
24.59
mmol/l
0.19
32
199
18
100
1.85
1.56
2.2
1.6
—
—
—
0
0
60
449
1.41
1.55
2.9
2.9
2.04
1.33
e6/l
0.30
24
228
35
502
0.66
1.53
1.3
1.3
0.73
1.50
u/ml
—
10
134
54
398
1.43
1.52
1.9
1.8
—
—
—
0
0
258
2394
1.38
1.52
28.9
16.1
47.68
25.85
mg/l
11.07
250
1957
166
1458
1.28
1.42
3.9
3.0
118.35
52.20
u/l
3.97
157
1352
207
2252
0.77
1.39
3.9
5.2
1.97
1.98
mu/l
0.04
183
2033
15
257
0.56
1.37
1.2
1.4
—
—
—
0
0
0
38
0.00
1.35
0.0
1.7
—
—
—
0
0
5
19
2.65
1.22
1.6
1.5
82.00
80.68
umol/l
—
5
19
38
276
1.43
1.18
4.1
3.3
—
—
—
0
0
135
1181
1.24
1.13
3.4
4.3
31.80
71.69
ng/l
0.86
107
918
16
96
1.70
1.12
1.1
1.3
—
—
—
0
0
5
21
2.40
1.09
1.0
1.0
—
—
—
0
0
102
1180
0.80
1.07
2.3
2.6
—
—
—
0
0
10
53
1.91
1.02
1.0
1.6
—
—
—
0
0
13
77
1.72
0.96
1.1
1.2
1.41
1.53
ratio
—
6
50
24
335
0.69
0.94
2.7
5.5
29.60
32.60
%
—
10
208
171
1855
0.83
0.88
3.3
4.0
15.18
15.14
pmol/l
0.06
148
1666
6
30
2.02
0.87
1.5
1.1
—
—
—
0
0
24
171
1.43
0.85
7.2
8.2
24.04
24.49
mmol/l
0.27
24
165
26
189
1.41
0.83
1.8
1.6
—
—
—
0
0
0
24
0.00
0.79
0.0
1.1
—
—
—
0
0
0
24
0.00
0.79
0.0
1.1
—
—
—
0
0
0
25
0.00
0.79
0.0
1.1
—
—
—
0
0
17
115
1.50
0.78
1.6
2.7
2.01
1.44
mmol/l
0.63
17
109
65
546
1.24
0.77
2.0
1.7
3.77
1.30
mg/l
2.65
59
436
7
38
1.86
0.74
1.4
1.1
—
—
—
0
0
5
26
1.94
0.71
1.8
1.0
—
—
—
0
0
5
27
1.86
0.68
1.2
1.2
—
—
—
0
0
5
28
1.80
0.66
1.2
1.2
—
—
—
0
0
5
28
1.80
0.66
1.2
1.2
—
—
—
0
0
5
29
1.73
0.64
1.2
1.2
—
—
—
0
0
5
29
1.73
0.64
1.2
1.2
—
—
—
0
0
5
29
1.73
0.64
1.2
1.2
—
—
—
0
0
23
174
1.35
0.61
1.4
2.5
1.89
1.16
%
1.38
23
174
0
22
0.00
0.59
0.0
1.1
—
—
—
0
0
10
65
1.55
0.56
1.8
1.2
—
—
—
0
0
81
903
0.86
0.53
1.7
1.8
19.93
20.06
nmol/l
0.03
68
757
22
170
1.31
0.53
1.4
2.4
0.89
0.60
%
1.22
22
170
68
598
1.17
0.52
3.6
4.6
97.62
227.18
ng/l
0.84
63
512
48
558
0.83
0.52
3.5
2.9
0.78
0.84
ug/l
0.26
32
384
6
40
1.51
0.52
3.0
3.5
7.42
12.59
pmol/l
—
6
40
9
65
1.39
0.51
1.8
1.2
—
—
—
0
0
12
84
1.44
0.50
1.3
1.3
0.00
0.00
g/l
-0.00
12
77
7
46
1.53
0.48
1.1
1.2
—
16.84
—
0
5
218
2267
0.88
0.48
30.8
15.8
74.63
72.33
ml/min/173m2
0.75
211
2107
105
1141
0.88
0.47
2.2
2.5
71.01
80.51
nmol/l
2.32
87
1002
28
228
1.25
0.47
3.0
3.6
74.66
93.18
ng/l
0.97
23
197
13
94
1.40
0.46
1.3
1.3
0.72
0.45
g/l
0.20
13
84
123
1315
0.89
0.42
2.0
2.3
94.73
94.80
pmol/l
0.00
70
674
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
15
0.00
0.41
0.0
1.0
—
—
—
0
0
0
15
0.00
0.41
0.0
1.0
—
—
—
0
0
0
15
0.00
0.41
0.0
3.9
—
—
—
0
0
15
114
1.33
0.41
1.3
1.3
8.51
7.70
g/l
1.04
15
102
15
114
1.33
0.41
1.3
1.3
4.39
3.70
g/l
0.65
15
102
15
114
1.33
0.41
1.3
1.3
4.17
4.23
g/l
0.07
15
102
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
20
159
1.27
0.41
2.1
2.9
25.82
25.20
mmol/l
0.36
20
150
57
639
0.87
0.41
3.5
4.5
1.02
1.02
kg/l
0.77
43
422
0
17
0.00
0.40
0.0
1.1
—
—
—
0
0
0
18
0.00
0.40
0.0
1.3
—
179.76
—
0
18
0
18
0.00
0.40
0.0
1.2
—
—
—
0
0
14
106
1.33
0.39
1.3
1.3
3.64
3.07
g/l
0.93
14
94
0
19
0.00
0.39
0.0
1.2
—
—
—
0
0
0
19
0.00
0.39
0.0
1.7
—
85.48
—
0
19
0
19
0.00
0.39
0.0
1.2
—
—
—
0
0
0
19
0.00
0.39
0.0
1.2
—
—
—
0
0
0
19
0.00
0.39
0.0
1.1
—
—
—
0
0
256
2487
1.14
0.39
19.2
10.3
30.44
24.58
u/l
2.20
247
2387
9
66
1.37
0.38
1.1
1.2
—
—
—
0
0
257
2498
1.13
0.38
31.6
20.8
137.89
139.71
mmol/l
15.91
251
2437
6
41
1.47
0.36
6.0
2.5
10.22
11.02
mmol/l
—
6
41
257
2501
1.13
0.36
31.9
20.9
4.00
4.01
mmol/l
0.41
251
2436
16
199
0.79
0.34
1.4
1.5
—
—
—
0
0
7
100
0.69
0.31
1.7
1.3
—
—
—
0
0
7
53
1.33
0.31
1.1
2.6
1.17
1.19
mmol/l
—
7
53
74
800
0.90
0.30
4.6
4.1
20.78
24.91
%
1.39
42
411
11
84
1.32
0.30
1.4
1.3
0.00
0.00
g/l
-0.00
11
73
7
55
1.28
0.30
1.1
2.5
102.43
105.33
mmol/l
—
7
55
17
205
0.82
0.29
1.2
1.4
—
—
—
0
0
24
205
1.18
0.28
1.8
2.7
121.83
129.68
g/l
1.05
24
197
193
1864
1.09
0.28
3.9
4.3
24.40
13.29
mm/h
7.41
177
1700
20
236
0.84
0.28
4.0
2.5
0.86
0.40
e6/l
0.39
20
217
5
71
0.70
0.26
1.2
1.2
—
—
—
0
0
5
40
1.25
0.22
1.2
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.8
—
184.73
—
0
11
0
11
0.00
0.21
0.0
1.2
—
273.83
—
0
6
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.8
—
4.63
—
0
8
258
2534
1.08
0.21
36.0
22.0
83.31
84.08
umol/l
0.13
252
2490
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
1.08
—
0
9
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
31
341
0.90
0.18
9.5
7.4
—
—
—
0
0
102
1063
0.94
0.18
2.8
3.4
1656.64
1757.68
ng/l
0.11
90
917
109
1133
0.94
0.18
2.9
2.9
308.67
127.82
ug/l
0.65
96
1029
61
646
0.93
0.17
1.8
1.9
485.93
436.06
pmol/l
0.27
47
530
20
177
1.14
0.16
2.5
3.7
47.86
48.85
%
0.06
20
172
98
1019
0.94
0.16
4.1
4.4
0.00
0.01
estimate
0.74
34
210
74
704
1.07
0.15
4.6
3.9
0.00
0.00
estimate
-0.00
34
209
8
97
0.82
0.14
1.0
1.0
—
—
—
0
0
80
768
1.05
0.13
4.1
4.1
0.00
0.00
estimate
-0.00
31
248
192
1885
1.04
0.12
35.6
19.8
14.90
13.78
%
11.34
192
1856
18
198
0.90
0.11
4.3
2.2
60.29
56.14
ml/min/173m2
—
7
81
5
61
0.82
0.08
2.4
1.1
—
—
—
0
0
5
64
0.78
0.08
1.4
1.8
—
—
—
0
0
31
294
1.06
0.07
2.0
2.7
2.71
7.10
ug/l
3.02
22
257
133
1350
0.97
0.06
3.8
4.3
0.00
0.03
estimate
0.79
35
264
130
1319
0.97
0.06
3.8
4.3
0.00
0.00
estimate
-0.00
37
272
132
1339
0.97
0.06
3.8
4.3
0.00
0.00
estimate
-0.00
37
280
258
2560
1.03
0.06
39.2
24.1
91.17
91.65
fl
0.64
252
2518
258
2561
1.03
0.05
39.3
24.1
4.11
4.43
e12/l
18.04
250
2481
258
2561
1.03
0.05
39.3
24.1
274.80
239.55
e9/l
6.79
249
2495
258
2561
1.03
0.05
39.7
24.5
36.85
39.84
%
17.82
252
2518
99
1007
0.97
0.05
4.5
4.4
2.76
2.17
ug/l
0.85
87
887
12
118
1.02
0.00
2.0
2.1
479.92
686.82
ug/l
0.19
12
111
25
249
1.00
0.00
2.8
1.7
399.32
386.47
nmol/l
0.08
25
224
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
1.20
—
0
5
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
5
50
1.00
-0.00
1.0
1.2
24.94
16.72
u/l
—
5
45
0
7
0.00
-0.00
0.0
1.3
—
9.44
—
0
7
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
7
74
0.94
-0.00
1.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
1734.33
—
0
6
0
9
0.00
-0.00
0.0
2.4
—
791.41
—
0
9
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
7
74
0.94
-0.00
1.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_DIGESTIVE_ORGANS_NAS – Malignant neoplasm of other and ill-defined digestive organs
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).